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Abstract
Cytosolic detection of pathogen associated molecular patterns is a key event in host discrimination
between commensal and pathogenic microbes. While cytosolic access is critical for the pathogenesis of
intracellular bacteria, access to the cytosolic compartment by extracellular bacteria is less well
understood. The leading extracellular pathogen Streptococcus pneumoniae (the pneumococcus)
activates intracellular innate immune responses, but unlike intracellular bacterial pathogens, S.
pneumoniae is killed and degraded upon uptake by phagocytic cells. The pneumococcus serially
colonizes the human upper respiratory tract and is eventually cleared over a period of weeks by the host
immune response. Previous studies have defined a critical role for the cytosolic pattern recognition
receptor Nod2 in driving the macrophage recruitment that leads to clearance of pneumococci, although
the mechanism by which pneumococcal cell wall components access the cytosol to activate Nod2
signaling remains unclear.
In these studies, we demonstrate that cytosolic access of pneumococcal components is dependent on
bacterial degradation by the host muramidase lysozyme and on the activity of the bacterial pore-forming
toxin pneumolysin. We propose a model in which S. pneumoniae is phagocytosed by macrophages
whereupon it is killed and degraded by lysozyme, allowing bacterial cell wall components to escape into
the host cell cytosol via the action of pneumolysin on the phagosome membrane. We further define a
host mechanism that limits the amount of pneumococcal products that transit to the cytosol, although
this defense is insufficient and the macrophage undergoes pro-inflammatory cell death.
This cell death is triggered by the formation of inflammasomes, multi-protein cytosolic complexes, that
activate caspase-1 to drive secretion of the pro-inflammatory cytokine interleukin-1 beta (IL-1β). We show
that sensing by the type 1 IL-1 receptor (Il1r1-/-) is required for the host to effectively recruit macrophages
to the nasopharynx and that Il1r1-/- mice have delayed bacterial clearance. Furthermore, sensing of IL-1
cytokines contributes to inflammation in the nasopharynx, which may promote S. pneumoniae growth or
transmission, but does not impact the adaptive immune response of the host. This suggests that a
bacterial toxin and the subsequent intracellular innate immune sensing it causes may help the
pneumococcus promote its extracellular lifestyle.
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ABSTRACT

THE ROLE OF CYTOSOLIC ACCESS IN STREPTOCOCCUS
PNEUMONIAE NASOPHARYNGEAL COLONIZATION

Jamie K. Lemon
Jeffrey N. Weiser

Cytosolic detection of pathogen associated molecular patterns is a key
event in host discrimination between commensal and pathogenic microbes.
While cytosolic access is critical for the pathogenesis of intracellular bacteria,
access to the cytosolic compartment by extracellular bacteria is less well
understood. The leading extracellular pathogen Streptococcus pneumoniae
(the pneumococcus) activates intracellular innate immune responses, but
unlike intracellular bacterial pathogens, S. pneumoniae is killed and degraded
upon uptake by phagocytic cells. The pneumococcus serially colonizes the
human upper respiratory tract and is eventually cleared over a period of
weeks by the host immune response. Previous studies have defined a critical
role for the cytosolic pattern recognition receptor Nod2 in driving the
macrophage recruitment that leads to clearance of pneumococci, although
the mechanism by which pneumococcal cell wall components access the
cytosol to activate Nod2 signaling remains unclear.
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In

these

studies,

we

demonstrate

that

cytosolic

access

of

pneumococcal components is dependent on bacterial degradation by the host
muramidase lysozyme and on the activity of the bacterial pore-forming toxin
pneumolysin. We propose a model in which S. pneumoniae is phagocytosed
by macrophages whereupon it is killed and degraded by lysozyme, allowing
bacterial cell wall components to escape into the host cell cytosol via the
action of pneumolysin on the phagosome membrane. We further define a
host mechanism that limits the amount of pneumococcal products that transit
to the cytosol, although this defense is insufficient and the macrophage
undergoes pro-inflammatory cell death.
This cell death is triggered by the formation of inflammasomes, multiprotein cytosolic complexes, that activate caspase-1 to drive secretion of the
pro-inflammatory cytokine interleukin-1 beta (IL-1β). We show that sensing
by the type 1 IL-1 receptor (Il1r1-/-) is required for the host to effectively
recruit macrophages to the nasopharynx and that Il1r1-/- mice have delayed
bacterial clearance. Furthermore, sensing of IL-1 cytokines contributes to
inflammation in the nasopharynx, which may promote S. pneumoniae growth
or transmission, but does not impact the adaptive immune response of the
host. This suggests that a bacterial toxin and the subsequent intracellular
innate immune sensing it causes may help the pneumococcus promote its
extracellular lifestyle.
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Introduction
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Historical Background
Streptococcus pneumoniae (the pneumococcus) was independently
isolated in 1880 by both George Sternberg in the United States (252) and
Louis Pasteur in France (209). Historically, Pasteur receives credit for the
discovery because he published three months before Sternberg, although
Pasteur’s experiments were actually performed later (11). Both men injected
human saliva subcutaneously into rabbits – for Pasteur the saliva was from a
child and for Sternberg the sample was his own saliva – and thereafter
recovered a lancet-shaped diplococcal bacterium from the blood of the
inoculated rabbits. This organism was first referred to as Pneumococcus in
1886 (82) for its association with pneumonia, and in 1920 it was renamed
Diplococcus pneumoniae to reflect both its cellular morphology and clinical
presentation

(281).

In

1974

it

received

its

current

designation

of

Streptococcus pneumoniae (64) because it grows in short chains in broth
culture, a defining characteristic of the Streptococcus genus. While initially
isolated from a state of carriage, within a decade of the pneumococcus’
discovery it had been recovered from cases of pneumonia (96, 153),
septicemia (258), meningitis (198), otitis media (289), and even arthritis
(274).
Although often studied for the variety of human diseases it can cause,
perhaps the most important contribution the pneumococcus has made to our
understanding of biology has little to do with its clinical manifestations in
humans.

!

In

1928

Fred

Griffith

published
2!

the

now

famous

‘Griffith’s

experiment’ that demonstrated the principle of bacterial transformation (95).
Griffith observed that injecting mice with an unencapsulated pneumococcal
strain caused no disease, while the mice rapidly succumbed to infection
following injection of an encapsulated strain. In his experiment, Griffith
injected mice with a mixture of live unencapsulated and heat-killed
encapsulated pneumococci. The mice quickly died and only live encapsulated
organisms could be recovered. As an added layer of detail, Griffith further
showed that the capsule type acquired by the live pneumococcal strain after
injection was always the capsule type of the heat-killed strain, even if that
capsule was a different type from the parental live strain. Avery and
colleagues built upon these observations and were able to reconstitute the
transformation reaction in vitro (3, 61, 62, 246). In their landmark paper
Avery, MacLeod, and McCarty provided definitive evidence that DNA was the
material responsible for the phenotypic changes observed during bacterial
transformation (14). This was the first demonstration that a nucleic acid
could have biologic functions and these findings eventually gave rise to the
field of molecular genetics.
In addition to aiding our understanding of fundamental biology,
research involving the pneumococcus has also led to discoveries of great
clinical importance. Shortly after the identification of the pneumococcus,
Christian Gram published his technique for staining clinical tissue samples to
aid in the identification of pathogenic organisms (93). Gram examined
samples from the lungs of 20 patients who had died of pneumonia. In 19 of
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the specimens he observed cocci that had not decolorized after anilinegentian violet staining (272), making S. pneumoniae the first identified
Gram-positive organism. Interestingly, in the one sample that had no Grampositive bacteria, Gram observed a bacterium that was readily decolorized
(Gram-negative), which is known today as Klebsiella pneumoniae. The
significance of this finding was not initially fully appreciated, resulting in
confusion about which organism was the true etiologic agent, though the
roles of both K. pneumoniae and the pneumococcus as causes of pneumonia
were eventually established (9). Nevertheless, Gram staining remains to this
day a primary means of pathogen identification in the clinical microbiology
laboratory.
The pneumococcus was also used in the first demonstration of
antibiotic resistance. In the beginning of the 20th century, researchers
observed that S. pneumoniae was sensitive to the quinine derivative
ethylhydrocupreine, also known as optochin, while similar bacterial species
were not (187). As part of this work, mice were infected with the
pneumococcus

and

then

experimentally

treated

with

optochin.

The

investigators rapidly isolated pneumococci that had developed resistance to
optochin (186). This experiment is additionally noteworthy as it is one of the
first examples of using a specific compound to treat an infection (272).

!
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Treatment and Vaccination
Early treatment for pneumococcal disease was based on findings from
studies conducted in rabbits at the end of the 19th century. In these
experiments it was observed that serum from rabbits previously infected with
pneumococci could protect against a secondary challenge with the same
bacterial strain (141). Later, it was established that the pneumococcal
capsular polysaccharide was the antigen responsible for this seroreactivity
(103), making it the first non-protein antigen to be identified (272), antisera
could be separated by strain type. The method of typing pneumococcal
strains used well into the 20th century, known as the Quellung reaction (199),
involves incubating pneumococci with the specific antisera. The reaction is
monitored for bacterial agglutination and swelling of the capsule, which
occurs only when the strain and antisera are of the same type. Once strains
could be reliably serotyped, patients with pneumococcal disease were
successfully treated through passive immunization with sera raised in horses
(80).
The success of serotherapy and development of antibiotics may have
actually delayed advances in the development of a vaccine for the
pneumococcus

(272).

The

first

vaccines

against

S.

pneumoniae

demonstrated that inoculation of purified capsule alone could generate
protective immunity

(76, 79, 159, 248) and that multiple polysaccharide

types inoculated at once were also effective (104, 134). These early vaccines
were removed from the market due to low usage (12) and were only
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revisited decades later as a result of the work of Robert Austrian.
Austrian developed a 14-valent capsule vaccine and demonstrated its
efficacy in preventing pneumococcal pneumonia (10, 13). The 14-valent
vaccine was introduced in 1977 and eventually expanded in 1983 to include
23 capsule types (230). Today this is still the broadest coverage of any
pneumococcal vaccine. However, the capsule vaccine had limited success in
protecting children due to lack of immunogenicity (172).
Following the introduction of the 7-valent pneumococcal conjugate
vaccine (PCV7) in the US in 2000, rates of both invasive pneumococcal
disease and pneumonia decreased dramatically (28, 94). This success was
due in large part because the vaccine is efficacious in young children, the
demographic most likely to contract pneumococcal disease (44). Similar
declines in pneumococcal-attributed childhood illnesses were also observed
internationally (70, 123), including in developing countries (43, 52, 92). This
is noteworthy because the relative distribution of pneumococcal serotypes
varies with geographic location (176) and PCV7 targeted the seven most
common serotypes in the developed world (249). Serotype coverage
expanded with introduction of the 13-valent conjugate vaccine (PCV13) in
2010 (201), however this still represents only a fraction of the known
pneumococcal serotypes that cause disease. In the years following vaccine
introduction, researchers observed that non-vaccine seroptypes began to
circulate more frequently in the population (1, 107), a phenomenon known
as ‘serotype replacement.’ The degree to which serotype replacement
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threatens to undermine the advances that vaccination has made against
pneumococcal disease is a subject of debate (30, 155), though current nextgeneration pneumococcal vaccines are focused on providing broader serotype
coverage (90, 158, 290), ideally at lower cost (183). This is critical, as
majority of the deaths attributed to pneumococcal disease today occur in the
developing world (152, 202, 283).
Despite the success of the polysaccharide and conjugate vaccines,
there were still an estimated 33,500 cases of invasive pneumococcal disease
and 3,500 deaths due to S. pneumoniae infection in the U.S. in 2013 (44).
The current treatment for pneumococcal infection is antibiotic therapy and
like many other pyogenic bacteria, the development of antibiotic resistance
remains a pertinent issue. The first patient to show clinical improvement
from penicillin treatment was suffering from pneumococcal conjunctivitis
(272) and the use of this antibiotic, as well as other β-lactams, remains
common today. However, within a couple decades of widespread usage,
penicillin-resistant pneumococci had been isolated clinically (100, 101). Rates
of antibiotic resistance, specifically to penicillin, increased to over 25% in the
U.S.

(108),

although

evidence

suggests

that

introduction

of

the

pneumococcal conjugate vaccine has reduced levels of antibiotic resistance
(53, 136).
The years following conjugate-vaccine introduction also saw decreased
pneumococcal disease in the elderly (94), a population that had not received
either PCV7 or PCV13. This ‘herd immunity’ - protection of an unvaccinated
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portion of the population - is attributed to the ability of the conjugate-vaccine
to reduce the carrier state in children (54, 180). Animal models have
demonstrated that this decrease in carriage is due to vaccine-induced
antibody blocking the acquisition of the pneumococcus in the upper
respiratory tract (232). The ability of the conjugate-vaccine to confer herd
immunity underscores a critical aspect of the pneumococcus’ lifestyle colonization and carriage in the hosts’ nasopharynx.

Pneumococcal Nasopharyngeal Colonization
Streptococcus pneumoniae serially colonizes the nasopharynx of
healthy humans. Colonization results in a suppurative rhinitis that is
characterized by increased mucus secretion. Recent animal studies have
demonstrated that these secretions are important for pneumococcal growth
(247) and are also believed to contribute to transmission (66, 228, 244).
Humans are the only natural host for pneumococci, and epidemiologic studies
show that transmission increases in high-density populations, such as
daycare centers, nursing homes, prisons, or within households (110, 177,
193, 200, 224). Until recently there were no tractable animal models of
pneumococcal

transmission.

The

current

model

of

pneumococcal

transmission relies on viral co-infection with Influenza A (66) and it appears
that the inflammation induced by viral infection is critical for transmission to
occur (244). Although this model has advanced our understanding of
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transmission, this aspect of pneumococcal pathogenesis remains vastly
understudied.
Colonization events can occur as early as the first day of life, with the
highest rates of carriage in children under the age of 2 (29). In this
population, the rate of colonization is estimated at 20-50% (29), though
some studies have reported carriage rates as high as 90% (71). Rates of
colonization decrease with increasing age (156) and in adults carriage is
estimated to be below 20% (29). Individuals can be colonized with multiple
distinct pneumococcal strains at the same time (8, 37).
Following

the

establishment

of

colonization,

pneumococci

are

subsequently cleared from the upper respiratory tract by the hosts’ immune
system. Clearance generally occurs over a period of a few weeks to a month
(173). However, colonization with the same serotype for a duration lasting
years has been reported (273). Nevertheless, this immune response is
unable to confer protection to the host and individuals may be re-colonized
throughout their lifetime.

Virulence Factors
The pneumococcus expresses several virulence factors that promote
its survival and growth in the human host. The nasopharynx is the site of
evolutionary pressure for S. pneumoniae; therefore, these factors generally
promote colonization and persistence, usually by mechanisms of immune
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evasion. However, they can also exacerbate disease processes, although
disease in the host is relatively rare and has no evolutionary benefit for the
bacterium (276).

Capsule
The capsular polysaccharide (Fig. 1.1), commonly referred to simply as
‘capsule,’ is comprised of long alternating sugar chains that are covalently
linked to the bacterial cell wall (256). This thick, sometimes mucoid (284),
‘sugar coating’ functions as a protective barrier between the bacterial cell and
the environment of the upper respiratory tract and is critical for successful
colonization of the nasopharynx (161).
Pneumococci of the same strain vary in the amount of capsule that
they express, a phenomenon known as phase variation (138, 277). Bacteria
that express high levels of capsule are called ‘opaque,’ a reference to their
colony morphology, whereas variants with a low abundance of capsule are
deemed ‘transparent.’ High levels of capsule expression aid in evasion of the
host immune system by preventing complement deposition on the bacterial
cell surface (119) and opsonophagocytic killing by phagocytes (137). Opaque
variants are favored during invasive disease (138), while transparent
variants are favored during colonization (277). Capsule can also prevent the
action of antibiotics that target pneumococcal cell wall enzymes, presumably
by blocking the ability of the antibiotic to penetrate to the cell surface (78).
There are over 90 known capsule types (106), which define the
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serotypes of pneumococci. The majority of capsules are negatively charged
(130), a feature that allows the pneumococcus to repel the negatively
charged mucus layer of the respiratory tract and prevents its clearance by
mucociliary beating (197). Some serotypes are more commonly associated
with invasive disease and differences in capsule type may contribute to the
site of infection (126) and overall prevalence in the population (275), though
this remains poorly characterized.

Pneumolysin
The pneumococcus expresses a single pore-forming toxin named
pneumolysin, which is a member of the cholesterol dependent cytolysin
(CDC) family. Pneumolysin is expressed as a 53-kDa monomer that
oligomerizes to form pores in cholesterol containing membranes (185, 270).
These pores can be up to 30 nm in diameter (144) and at high
concentrations can cause eukaryotic cell lysis (245). The CDC toxin family
spans more than 20 bacterial species and all CDC toxins have a highly
conserved tryptophan-rich undecapeptide region, which is critical for toxin
insertion into host membranes (235, 265). In the case of pneumolysin, a
single residue mutation in the undecapeptide results in near complete loss of
toxin function (144), though binding to cholesterol occurs through residues
outside of the undecapeptide region (73).
Pneumolysin is unique among the CDC toxin family because it lacks an
N-terminal secretion signal sequence (270). It is known to be associated with
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the bacterial cell wall (218, 219), though the exact mechanism of its release
is still not well defined. It was originally believed that pneumolysin secretion
was dependent on bacterial autolysis (181). However, pneumococcal strains
lacking LytA – the autolytic amidase – are still able to secrete pneumolysin
(15). Pneumococcal degradation by the host enzyme lysozyme, which
hydrolyzes the glycan backbone of peptidoglycan, can cause the release of
pneumolysin in broth culture (60).
Nearly

all

clinically

isolated

strains

of

pneumococci

express

pneumolysin (131), underscoring its important role in disease, as well as its
evolutionary

importance

to

the

bacterium.

Pneumolysin

induces

inflammation at the mucosal surface, though how this contributes to the
organisms’ virulence appears to vary by site of infection or pneumococcal
strain (126, 205). Pneumolysin-deficient strains are highly attenuated in
multiple disease models (22, 23, 31, 236). Somewhat paradoxically,
pneumolysin

does

not

promote

the

establishment

of

nasopharyngeal

colonization (237) and pneumolysin expression drives host clearance of
colonization (171, 267). A mutated strain containing a full deletion of the
pneumolysin gene has prolonged carriage in the nasopharynx compared to
the isogenic wild type strain (171, 267) and exactly how pneumolysin
contributes to the persistence of S. pneumoniae in the host or the population
remains an open question.
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Other Virulence Factors
Although capsule is the immunodominant pneumococcal antigen, the
pneumococcal surface protein A (PspA) can elicit cross-reactive antibodies
(33). Vaccination with PspA can confer protection against pneumococcal
colonization (204), pneumonia (34), and sepsis (255) in murine models.
PspA is under active investigation as a potential vaccine target (194) because
it is abundantly expressed in all pneumococcal strains and could offer
broader strain coverage than is currently available. PspA prevents the
deposition of complement onto the bacterial cell surface (226, 227, 264) by
competitively inhibiting the binding of C-reactive protein (CRP) (190).
Phosphocholine (ChoP), the moiety that is targeted by CRP, anchors the
choline binding proteins, including PspA, to the bacterial cell surface (81,
288). Prevention of CRP binding promotes virulence in sepsis models by
inhibiting the alternative pathway of complement activation (227, 264). PspA
also binds lactoferrin (99, 102), a glycoprotein that sequesters iron, as well
as apolactoferrin (242), an iron-free form of lactoferrin. Apolactorferrin has
bactericidal properties and binding by PspA promotes pneumococcal survival
(242). It is speculated that PspA-mediated interactions with lactoferrin
promote iron scavenging by S. pneumoniae, though whether this contributes
to bacterial growth in vivo has not been resolved.
Similar to many other bacterial pathogens and residents of the
mucosal flora (32, 85, 86, 143, 188, 214, 215, 217), S. pneumoniae
expresses a protease that specifically cleaves human immunoglobulin A1

!

13!

(IgA1) (271). Evasion of this host immunoglobulin in the upper respiratory
tract is critical for bacterial persistence, as IgA1 comprises over 90% of the
mucosal IgA (140). The pneumococcal IgA1 protease cleaves the hinge
region of IgA1, separating the FC domain from the antigen-binding Fab
fragments. This protease promotes bacterial adherence (278) and prevents
complement deposition and opsonophagocytic killing in vitro (74), though its
specificity for human IgA1 has made in vivo animal studies challenging.
Recently, however, experiments using mice passively immunized with
monoclonal

human

IgA1

demonstrated

that

IgA1

protease

promotes

pneumococcal colonization in vivo (124).
Pneumococcal strains express up to three neuraminidases (211),
which cleave terminal sialic acid residues from mucins and cell surface
glycans in the upper respiratory tract. These neuraminidases promote
colonization in the nasopharynx (165, 262) by liberating nutrients for
bacterial growth (247) and possibly exposing surface receptors required for
adherence to the epithelial surface (210). S. pneumoniae also alters its cell
wall structure to enhance resistance to the host muramidase lysozyme, which
is abundantly expressed on the mucosal surface (49). This modification is
energetically costly, but provides an advantage for colonizing organisms
(59), although the pneumococcus still remains susceptible to lysozyme
degradation by phagocytes (60).
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Immune recognition of S. pneumoniae colonization
A well-defined murine model of S. pneumoniae nasopharyngeal
carriage (174), in which unanesthetized mice are intranasally inoculated with
pneumococci to restrict bacterial colonization to the upper respiratory tract,
has allowed us to further characterize both the host and bacterial factors that
contribute to the dynamic process of colonization in the nasopharynx. This
model has been validated by experimental human carriage studies with the
same pneumococcal strain (173) and has contributed specifically to the
elucidation

of

the

host

immune

cell

populations

that

respond

to

pneumococcal colonization and lead to eventual bacterial clearance.

Neutrophils
Neutrophils are professional phagocytic cells that are critical in host
defense against bacterial and fungal infections. During S. pneumoniae
colonization, neutrophils are recruited to the upper respiratory tract early in
infection, with peak influx generally between one and three days after
bacterial inoculation (197, 291). They can be visualized by microscopy in the
lumen of the nasopharynx, where they are associated with pneumococci
(127). The ability of neutrophils to phagocytose and kill S. pneumoniae has
been examined ex vivo and these studies have demonstrated that bacterial
uptake is promoted by opsonization with anti-pneumococcal antibody that
facilitates

complement

deoxyribonuclease
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(35).

S.

resistance

pneumoniae
to

killing

expresses
by

a

neutrophil

extracellular traps (NETs) (20). Instead, bacterial killing by neutrophils is
dependent on the action of serine proteases following phagocytosis (251).
Neutrophil numbers in the nasopharynx wane shortly after the
establishment of colonization (291). Their influx has minimal impact on
bacterial numbers in the upper respiratory tract (171, 291), indicating that
they are insufficient to effectively remove the pneumococcus from its niche
before type-specific antibody develops. Nevertheless, depletion of neutrophils
during colonization with an invasive pneumococcal strain significantly
increases mortality in a mouse model (171), suggesting that although they
do not promote clearance of nasal carriage, neutrophils are critical for host
protection from invasive disease.

Macrophages
During S. pneumoniae colonization macrophages are recruited to the
upper respiratory tract following initial influx of neutrophils. Their presence
peaks by day five post colonization and is maintained for the duration of
carriage (60, 291). Depletion of these macrophages through intranasal
administration of clodronate lipososmes results in higher bacterial burden
and a significantly longer duration of colonization (291), demonstrating their
importance for effective bacterial clearance.
Host expression of the C-C chemokine receptor type 2 (CCR2), which
is present on the surface of inflammatory monocytes, is also required for
proper macrophage recruitment. Mice that are deficient in CCR2 expression
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(Ccr2-/-) have significantly lower numbers of nasopharyngeal macrophages
over the duration of a colonization event (60), which results in an increased
and sustained burden of pneumococci. The C-C chemokine ligand 2 (CCL2)
binds CCR2 with the highest affinity of any CCR2 ligand (280) and further
investigation showed that CCL2 is produced by macrophages in vitro
following infection with pneumococci (60). Furthermore, these studies
demonstrated that CCL2 production is dependent on bacterial expression of
the pore-forming toxin pneumolysin, as well as host expression of the
muramidase lysozyme.
Similar to neutrophils, macrophages kill S. pneumoniae through
phagocytosis and degradation. Although opsonization and complement
deposition promote pneumococcal uptake (56), macrophages are able to
phagocytose pneumococci in the absence of these components, through
scavenger receptor-mediated binding to the bacterial surface. Expression of
the scavenger receptor SR-AI/II on alveolar macrophages protects against
pneumococcal pneumonia by facilitating bacterial up-take (7). Additionally,
the scavenger receptor macrophage receptor with collagenous structure
(MARCO) is important in host defense against both pneumonia and S.
pneumoniae colonization (6, 67).
Following uptake, pneumococci localize to the phagosome (91), which
rapidly acidifies (139, 286), resulting in bacterial death (125). Nitric oxide
production is important for S. pneumoniae killing by macrophages (167),
although contributions of additional factors, such as proteases and other

!

17!

degradative enzymes, has not been reported.

Humoral Immune Responses
The successes of serotherapy and the pneumococcal vaccines clearly
demonstrate that high titers of anti-pneumococcal antibodies can protect
against disease. Patients with genetic mutations impairing development of
antibodies are more susceptible to pneumococcal infection (150), further
indicating an important role for antibody-mediated protection, which is
believed to be due to increased opsonophagocytic killing by neutrophils (35).
Antibodies

induced

by

vaccination

can

reduce

host

susceptibility

to

colonization (54, 180) and studies of experimental human carriage have
shown that higher antibody titers correlate with lower pneumococcal
numbers in the nasopharynx (173).
Colonization results in the production of both IgA and IgG antibodies
that detect the pneumococcal capsule and surface proteins (60, 173, 174,
231, 233). Although antibody can block the acquisition of colonization (232),
humoral responses are insufficient to clear pneumococci from an already
colonized host (174) and natural immunity to S. pneumoniae colonization
occurs independent of serotype (156), suggesting that other adaptive
immune responses are required to achieve clearance.

Cellular Immune Responses
HIV-positive individuals are more susceptible to pneumococcal disease
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and lower CD4+ cell counts correlate with increased risk of infection (68),
indicating that cellular immunity is critical for protection in the human host.
Effective clearance of pneumococcal colonization in a murine model requires
immunity acquired through CD4+ T-cells (106, 164), which is attributable
specifically to the interleukin-17a (IL-17a) producing Th17 sub-population of
CD4+ T-cells (130, 164, 291). Depletion of these cells during primary
colonization prolongs bacterial carriage and dampens host responses to a
secondary colonization event (291). These defects correlate with reduced
numbers of macrophages and neutrophils during primary and secondary
colonization, respectively (291).

Innate Immune Detection of S. pneumoniae
Hosts, from Drosophila to humans, express a finite set of genetically
encoded ‘pattern recognition receptors’ (PRRs) (257). These receptors are
highly expressed in cells of the innate immune system and detect conserved
bacterial and viral motifs commonly called pathogen associated molecular
patterns (PAMPs). PAMPs range from nucleic acids to secretion systems and
host recognition of these signatures activates pro-inflammatory signaling
cascades that drive innate immune defense. PRRs can broadly be classified
by cellular localization and include the membrane-bound Toll-like receptors
(TLRs) and C-type lectin receptors (CLRs), as well as the cytosolic Nod-like
receptors (NLRs), AIM2-like receptors (ALRs), and (RIG)-I-like receptors
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(RLRs).

Extracellular Receptors
The TLRs sample the extracellular milieu encountered by host cells.
They sense a diversity of bacterial and viral ligands and their activation
results

in

signaling

cascades

that

drive

pro-inflammatory

cytokine

production. All TLRs, except for TLR3, employ myeloid differentiation primary
response gene 88 (MYD88) as an adaptor molecule for signaling. Humans
with mutations in either MYD88 or interleukin-1 receptor-associated kinase 4
(IRAK-4), a downstream kinase involved in TLR signaling, are acutely
susceptible to pneumococcal disease (21, 213). Studies investigating the
association of pneumococcal disease with polymorphisms in individual TLRs
have

yielded

inconsistent

findings

(182,

260),

suggesting

a

possible

redundancy with other innate immune pathways that signal through MYD88
and IRAK-4.
Pneumococcal lipoproteins and lipoteichoic acid activate TLR2 both in
vitro (18, 240, 261) and in the respiratory tract epithelium during S.
pneumoniae

colonization

(291).

Mice

deficient

in

TLR2

(Tlr2-/-)

have

increased susceptibility to invasive pneumococcal disease (19) that may be
attributable to disruption of the epithelial barrier (19, 47), which allows
greater access to the bloodstream and other sterile sites. Tlr2-/- mice also
have prolonged bacterial carriage and reduced numbers of macrophages
recruited to the nasopharynx (291). There are reports that TLR2 is activated
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by peptidoglycan from Gram-positive bacteria (241, 287), though the
veracity of this observation remains a matter of debate (263).
TLR4, which is classically activated by the lipopolysaccharide (LPS) of
Gram-negative

bacteria,

is

also

reported

to

directly

recognize

the

pneumococcal pore-forming toxin pneumolysin and protect against bacterial
infection (162, 250). Others (2, 184, 267), however, have observed no effect
of TLR4 in S. pneumoniae detection and the exact role of this TLR in
recognition of pneumococci remains unclear.
In vitro studies have shown that TLR9, which recognizes CpG motifs
within bacterial DNA (105), is activated upon S. pneumoniae infection with
live, but not heat-killed, bacteria (184). Further investigations have defined a
role for TLR9 activation in early defense against pneumococcal disease in
vivo, however no effect on colonization has been observed (2).

Intracellular Receptors
NLRs are a family of cytosolic PRRs that are characterized by a
nucleotide oligomerization-binding domain (Nod) as well as C-terminal
leucine-rich repeats, which are critical for ligand recognition and binding
(122, 259). Nod1 and Nod2 detect bacterial peptidoglycan and trigger a
signaling cascade that drives pro-inflammatory cytokine production through
activation of the transcription factor nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB). Both Nod1 and Nod2 contain Nterminal CARD domains, which facilitate signaling through homotypic CARD-
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CARD interactions with their common adaptor protein receptor-interacting
protein 2 (RIP2) (24, 120, 121, 203). Nod 1 recognizes the meso-DAP motif
of peptidoglycan from Gram-negative bacteria (87), as well a few select
Gram-positive organisms, including Listeria and Bacillus species (45). Nod2
detects the muramyl dipeptide (MDP) found in the cell wall of all bacterial
species (88).
Nod2 detection of S. pneumoniae peptidoglycan during colonization
contributes to macrophage driven bacterial clearance (60). In vitro studies
have shown Nod2-dependent production of pro-inflammatory cytokines,
including

interleukin-6

(IL-6)

and

CCL2,

following

incubation

with

pneumococci (60). In vivo, host expression of CCR2, the receptor for CCL2,
is required for increased macrophage presence in the nasopharynx, as well
as subsequent bacterial clearance. In these studies, increased cytokine levels
were dependent on host expression of lysozyme and bacterial production of
pneumolysin (60), implicating a role for bacterial degradation and toxin
release.
Intracellular bacterial pathogens use a variety of strategies to access
the cytosol. These mechanisms may provide insight into how pneumococcal
products transit into the host cell cytosol (Fig. 1.2). Unlike the model
intracellular organisms Listeria monocytogenes, which escapes from the
phagosome into the cytosol (216), or Salmonella, which replicates inside a
cellular vacuole (268), S. pneumoniae is killed and degraded following
phagocytosis. However, all of these microbes activate intracellular host PRRs
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(60, 268). L. monocytogenes uses its CDC toxin to perforate and destabilize
the phagosome membrane, allowing intact bacteria to access the cytosol
where they replicate and spread to other cells (216). Salmonella uses a type
III secretion system to inject effector proteins into the cytosol, which
remodel the phagosome to transform it into a hospitable replicative niche. S.
pneumoniae has no known specialized secretion system, but it does express
pneumolysin. It is possible the pneumolysin facilitates transit of bacterial
components

across

the

phagosome

membrane,

however,

the

exact

mechanism by which pneumococcal cell wall components access the host cell
cytosol to activate Nod2 remains unclear.
A subset of NLRs and ALRs trigger a defense mechanism known as
inflammasome

activation.

When

this

type

of

defense

occurs

an

inflammasome complex, comprised of receptors and adaptor proteins,
oligomerizes in the cytosol, causing activation of caspases 1 and 11 (149).
The maturation of caspases 1 and 11 into their enzymatically active forms
leads to the production of mature interleukin-1 beta (IL-1β) and interleukin18 (IL-18), ultimately resulting in the pro-inflammatory death of the host cell
(51, 148, 169). Caspase-11 is activated by the acylated lipid A of LPS (98,
137), and therefore detects many intracellular Gram-negative bacterial
pathogens (36, 41, 42, 221).
Caspase-1 maturation can result from the activation of a variety of
receptors, which detect a diversity of conserved virulence patterns including
cytosolic flagellin (4, 83, 178), DNA (77, 114, 192), bacterial secretion
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systems (179), and membrane damage (148, 191). S. pneumoniae was first
characterized to activate the NLRP3 inflammasome (175) and subsequent
study revealed that it also activates the AIM2 inflammasome (72). Although
they recognize different stimuli, both the NLRP3 and AIM2 inflammasomes
assemble through the homotypic interactions of pyrin domains (PYD) at their
N-termini with the PYD of the adapter molecule apoptosis-associated specklike protein containing a CARD (ASC). ASC then recruits procaspase-1
through interactions between its caspase activation and recruitment domain
(CARD) and the CARD domain of caspase-1. Recruitment of caspase-1 to this
complex results in its activation (238), through what is believed to be an
auto-processing mechanism similar to activation of caspases 8 and 9 during
intrinsic and extrinsic apoptosis (229), although this has not yet been
formally demonstrated.
Activation of the NLRP3 inflammasome by S. pneumoniae occurs in
multiple cell types including macrophages (72, 282), dendritic cells (175),
and

neutrophils

(133)

and

is

dependent

on

bacterial

expression

of

pneumolysin. Incubating recombinant pneumolysin with host cells in vitro
results in NLRP3 dependent pro-inflammatory cell death (175), presumably
through action of the toxin at the plasma membrane. In contrast, when
phagocytes are infected with live bacteria, NLRP3 and AIM2 mediated cell
death is dependent on both bacterial uptake and expression of pneumolysin
(72). This suggests that in the context of infection with the entire organism,
rather than just its toxin, delivery of inflammasome activating ligands does
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not occur across the plasma membrane.
The role of inflammasome activation and subsequent IL-1β secretion
during in vivo infection has only been partially addressed. Mice deficient in
the NLRP3 receptor or ASC adaptor protein had increased bacterial burden
and decreased survival in a pneumococcal pneumonia model (72, 175).
Similar results were also observed in a model of pneumococcal corneal
infection

(133).

Whether

inflammasome

activation

occurs

during

pneumococcal colonization and promotes host defense remains to be
explored. Given that the pneumococcus activates other cytosolic sensing
systems and carriage induces inflammation, it is plausible that IL-1β
secretion occurs during colonization and may contribute to eventual bacterial
clearance.
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Figure 1.1. Streptococcus pneumoniae morphology.
(A) Electron micrograph of the type 23F S. pneumoniae strain used in these
studies. Black arrow indicates the capsular polysaccharide (‘capsule’). Scale
bar represents 500 nm.
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Figure 1.2. Bacterial strategies to access the cytosol.
(A) The intracellular bacterial pathogens Listeria monocytogenes and
Salmonella use pore-forming toxins and secretion systems respectively, to
gain access to the host cell cytosol to promote their survival. S. pneumoniae,
in contrast, is killed and degraded, although it activate cytosolic pattern
recognition receptors, suggesting cytosolic access occurs during infection.
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Aims of Dissertation
The work presented in this dissertation was designed to address the following
aims:
1) To determine the mechanism by which S. pneumoniae products access the
host cell cytosol during infection of macrophages
Previous studies from our lab have defined a critical role for
macrophages in the clearance of pneumococci from the host nasopharynx.
This macrophage influx is dependent on Nod2 recognition of intracellular
pneumococcal peptidoglycan, which triggers the expression and secretion of
the macrophage chemokine CCL2. Production of CCL2 by macrophages in
vitro is dependent on bacterial expression of the pneumococcal pore-forming
toxin, pneumolysin. Pneumolysin can be released following bacterial lysis by
the host muramidase lysozyme. Together these data suggest that cytosolic
access occurs following phagocytosis and lysozyme-mediated bacterial
degradation that releases pneumolysin, allowing transit of pneumococcal
components across the phagosome membrane. Although signaling data
support this hypothesis, quantification of pneumococcal components in the
host cell cytosol remains to be formally demonstrated.
To assess the mechanism of cytosolic access of pneumococcal
components we adapted a detergent-based cellular fractionation assay to
measure levels of capsular polysaccharide in the host cell cytosol following
infection. This allowed us to interrogate both the host and bacterial factors
that contribute to intracellular detection of S. pneumoniae.
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2) To determine the consequences of cytosolic access on S. pneumoniae
nasopharyngeal colonization
In vitro studies from other investigators have demonstrated that
infection of phagocytes with S. pneumoniae results in activation of cytosolic
innate immune sensors other than Nod2, including multiple receptors
involved in inflammasome signaling. A protective role for both inflammasome
components and IL-1β, the pro-inflammatory cytokine produced during
inflammasome activation, against pneumococcal disease has already been
defined. However, the contribution of these cytokines to pneumococcal
colonization and the host response to carriage has not been investigated.
To determine the possible effects of inflammasome-derived cytokines
on pneumococcal colonization, we intranasally inoculated type 1 IL-1
receptor-deficient mice (Il1r1-/-) and monitored both bacterial density and
host cell infiltrate in the nasopharynx. We further employed quantitative RTPCR to characterize the chemokine profile of colonized Il1r1-/- mice, which
may contribute to altered host responses during S. pneumoniae carriage.
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CHAPTER II

Degradation products of the extracellular pathogen
Streptococcus pneumoniae access the cytosol
via its pore-forming toxin

The contents of this chapter were originally published as:
Lemon JK, Weiser JN. 2015. Degradation products of the extracellular
pathogen Streptococcus pneumoniae access the cytosol via its pore-forming
toxin. mBio 6(1):e02110-14.
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Abstract
Streptococcus pneumoniae is a leading pathogen with an extracellular
lifestyle, however, it is detected by cytosolic surveillance systems of
macrophages. The innate immune response that follows cytosolic sensing of
cell wall components results in recruitment of additional macrophages, which
subsequently clear colonizing organisms from host airways. In this study, we
monitored cytosolic access by following the transit of the abundant bacterial
surface component capsular polysaccharide, which is linked to the cell wall.
Using confocal and electron microscopy, we characterized the location of cell
wall components in murine macrophages, and found that they are distributed
outside

of

membrane-bound

organelles.

Quantification

of

capsular

polysaccharide through cellular fractionation demonstrated that cytosolic
access of bacterial cell wall components is dependent on phagocytosis,
bacterial sensitivity to the host degradative enzyme lysozyme, and release of
the pore-forming toxin pneumolysin. Activation of p38 MAPK signaling is
important for limiting access to the cytosol, however ultimately these are
catastrophic events for both the bacteria and the macrophage, which
undergoes cell death. Our results show how expression of a pore-forming
toxin ensures the death of phagocytes that take up the organism, although
cytosolic sensing results in innate immune detection that eventually allows
for successful host defense. These findings provide an example of how
cytosolic access applies to an extracellular microbe and contributes to its
pathogenesis.
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Importance
Streptococcus pneumoniae is a bacterial pathogen that is a leading
cause of pneumonia. Pneumococcal disease is preceded by colonization of the
nasopharynx, which lasts several weeks before being cleared by the host’s
immune system. Although S. pneumoniae is an extracellular microbe,
intracellular detection of pneumococcal components is critical for bacterial
clearance. In this study, we show that following bacterial uptake and
degradation by phagocytes, pneumococcal products access the host cell
cytosol via its pore-forming toxin. This phenomenon of cytosolic access
results in phagocyte death and may serve to combat the host cells
responsible for clearing the organism. Our results provide an example of how
intracellular access and subsequent immune detection occurs during infection
with an extracellular pathogen.
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Introduction
Cytosolic detection of pathogen associated molecular patterns is a key
event in host discrimination between commensal and pathogenic microbes.
While cytosolic access is critical for the pathogenesis of intracellular bacteria,
access to the cytosolic compartment by bacteria with an extracellular lifestyle
remains poorly understood. One such pathogen that has been shown to
activate cytosolic sensing is Streptococcus pneumoniae, a Gram-positive
bacterium that serially colonizes the human upper respiratory tract (URT)
and is a leading cause of bacterial pneumonia (202). Colonization of the
upper airway precedes invasive pneumococcal disease (29) and is normally
cleared by the host immune response within several weeks (173). A murine
model of S. pneumoniae colonization has demonstrated that clearance of
pneumococcal colonization requires a sustained presence of macrophages in
the URT (291), similar to the observation that alveolar macrophages are
critical for host defense in the lower respiratory tract (142).
The

macrophage

driven

clearance

of colonizing

pneumococci is

dependent on host expression of the cytosolic Nod-like receptor Nod2 (60).
Recognition of the cell wall component peptidoglycan by Nod2 activates NFκB signaling (88, 203, 259), resulting in expression of pro-inflammatory
cytokines, including the monocyte chemoattractant protein CCL2 (or MCP-1).
Macrophage recruitment to the URT, as well as subsequent bacterial
clearance, is dependent on production of CCL2 in vivo and in vitro requires
bacterial expression of the pneumococcal pore-forming toxin, pneumolysin
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(60).
Pneumolysin,

a

CDC

toxin,

is

expressed

as

a

monomer

that

oligomerizes to form a pore up to 30 nm in diameter in cholesterol containing
membranes (144). Pneumolysin is unique among the CDC family of toxins in
that it lacks an N-terminal secretion signal sequence (270), but bacterial
degradation by the muramidase lysozyme can cause its release in broth
culture (59). Host expression of lysozyme is also required for clearance of
pneumococcal colonization (60), suggesting that release of pneumolysin
following lysozyme degradation allows peptidoglycan to access the host cell
cytosol, where it is sensed by Nod2, eventually resulting in CCL2 production
and clearance of colonization. Pneumolysin has been shown to facilitate
cytosolic access of cell wall from other bacterial species in epithelial cells for
sensing by Nod1 (222), though the mechanism by which Nod2 activation
occurs in phagocytes remains to be determined.
Here we show that pneumococcal cell wall associated components
escape

into

the

cytosol

of

macrophages

following

phagocytosis

and

degradation. Access to the cytosol is mediated by the pore-forming toxin
pneumolysin and is dependent on the ability of pneumolysin to bind host cell
membranes. While the host cell has defenses to limit the amount of bacterial
products that escape the phagosome, cytosolic access ultimately leads to the
pro-inflammatory death of the macrophage.
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Results
Pneumococcal components access the cytosol of macrophages
The process of cytosolic access was monitored by following the transit
of the bacterial surface component capsular polysaccharide (CPS), which is
covalently linked to the cell wall (256). CPS was chosen as a proxy for cell
wall because it is abundant, long lived in the host cell, and easily detectable.
To visualize pneumococcal fragments we incubated murine bone marrow
derived

macrophages

(BMMs)

with

S.

pneumoniae

and,

following

phagocytosis and degradation, conducted immunofluorescence staining for
the pneumococcal CPS and the phagolysosome marker, LAMP1. By confocal
microscopy, we observed CPS staining within LAMP1-positive vesicles (Fig.
2.1A, white open arrow), as well as smaller foci of CPS that do not co-localize
with the phagolysosome marker (Fig. 2.1A, white closed arrows). To address
whether these fragments were in other membrane-bound organelles, we
conducted immuno-gold labeling and electron microscopy of BMMs incubated
with pneumococci. We observed immuno-gold staining for CPS both within
the phagosome and outside of any membrane-bound compartment by 45
minutes after infection (Fig. 2.1C, red arrows). At three hours post-infection
the bacteria appeared fully degraded, but gold labeling of CPS was still visible
both within and outside the phagosome (Fig. 2.2). Uninfected macrophages
had no detectable immuno-gold labeling for CPS (data not shown). These
results suggest that pneumococcal products are present in the host cell
cytosol following bacterial degradation by BMMs.
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The amount of pneumococcal products in the cytosol was more
precisely

quantified

by

adaptation

of

a

detergent

based

sub-cellular

fractionation assay. Following infection with S. pneumoniae, BMMs were
permeabilized with detergents to lyse either all host cell membranes or
selectively lyse the plasma membrane. The resulting supernatants were
ultracentrifuged to generate purified fractions representing either the cytosol
or whole cell contents. The purity of these fractions was validated by western
blotting for proteins present in either the cytosol (LDH) or lysosome
(Cathepsin B) (Fig. 2.3A), and the amount of pneumococcal CPS in each
fraction was quantified by ELISA. The percentage of CPS present in the
cytosol fractions was calculated as a proportion of the CPS measured in the
whole cell fractions and was significantly higher than background levels of
contamination, which were determined by ELISA for the lysosome protein
Cathepsin B (Fig. 2.3B). A S. pneumoniae strain lacking two cell wall
modifying enzymes, making it hypersensitive to degradation by the host
enzyme lysozyme (pgdA-/adr-) had significantly higher amounts of CPS in
the cytosol fraction compared to a wild type (WT) pneumococcal strain (Fig.
2.3B), though no difference in total bacterial uptake was observed between
the two strains, as measured by CPS in the whole cell fractions (Fig. 2.3C).
In a gentamicin protection assay, both the WT and the pgdA-/adr- strains
were killed over a 30 minute infection, though this process was more rapid
for the pgdA-/adr- mutant (Fig. 2.3D). BMM killing of the pgdA-/adr- mutant
strain was largely lysozyme dependent (Fig. 2.3E), correlating with the lack
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of intracellular signaling previously observed in lysozyme deficient BMMs
(60). Since the pgdA-/adr- strain had significantly higher levels of CPS
present in the cytosol compared to the WT strain, unless otherwise specified,
subsequent experiments used this lysozyme sensitive S. pneumoniae mutant
in order to interrogate the host and bacterial factors mediating access of
pneumococcal cell wall products to the cytosol.

Access to the cytosol is dependent on phagocytosis and pneumolysin
To address the role of bacterial uptake in cytosolic access of
pneumococcal cell wall components, we treated BMMs with cytochalasin D
(CytD), an inhibitor of actin polymerization, to block phagocytosis. Following
infection with S. pneumoniae (Spn), the presence of CPS in the whole cell
fractions of host cells was blocked by incubation with CytD (Fig. 2.4A). The
presence of CPS in the cytosol fractions upon infection with pneumococci was
similarly

dependent

demonstrate

that

on

bacterial

cytosolic

uptake

access

of

(Fig.

2.4B).

pneumococcal

These
CPS

results
requires

phagocytosis.
The pneumococcal pore-forming toxin, pneumolysin, is required for
activation of cytosolic host signaling pathways (60). The role of pneumolysin
in cytosolic access of pneumococcal cell wall components was assessed by
quantifying the amount of capsule present in the cytosol of BMMs infected
with a lysozyme sensitive S. pneumoniae strain containing an unmarked,
complete in-frame deletion of the pneumolysin gene (ply-). The absence of
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pneumolysin had no effect on the ability of host cells to take up
pneumococci, as seen by similar levels of CPS in the whole cell fractions (Fig.
2.5A). However, compared to a bacterial strain expressing WT pneumolysin,
the ply- mutant had significantly less CPS present in the host cell cytosol
(Fig. 2.5B). The loss of pneumolysin expression had no effect on intracellular
bacterial killing (Fig. 2.5C). A pneumococcal strain expressing a pneumolysin
toxoid, containing alanine mutations in the two residues that bind cholesterol
(plyTL

→

AA)

(73), which is deficient in pore-formation as assessed by hemolysis

assay (Fig. 2.6A), but has no defect in amount of pneumolysin protein
expressed (Fig. 2.6B), similarly had significantly reduced levels of CPS in the
cytosol fraction (Fig. 2.5B). Reintroduction of the pneumolysin gene to
correct the mutation (ply+) fully restored the presence of CPS in the host cell
cytosol (Fig. 2.5B). Together, these data show that pneumolysin and
specifically toxin binding of the host-membrane are required for cytosolic
access of pneumococcal cell wall components.

Cytosolic access is independent of TLR4 and acidification and is attenuated by
p38 MAPK activation
Toll-like receptor 4 (TLR4) has been reported to aid in host defense
through detection of pneumolysin (162). To determine the role of TLR4 in
cytosolic access of pneumococcal products, we differentiated BMMs from
C57BL/6 (WT) and Tlr4-/- mice, infected them with pneumococci, and
quantified the presence of CPS by fractionation and ELISA. We observed no
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difference in the amount of total bacterial capsule in the Tlr4-/- macrophages
compared to WT macrophages (Fig. 2.7A) and there was no significant
difference in the amount of CPS in the cytosolic fractions between WT and
Tlr4-/-

macrophages

(Fig.

2.7B).

Cytosolic

access,

therefore,

occurs

independently of TLR4 activation.
Acidification of the phagosome occurs rapidly following bacterial
uptake. Whether phagosome acidification is required for bacterial products to
escape into the cytosol was ascertained by incubating BMMs with bafilomycin
A (BAF), a specific inhibitor of the vacuolar ATPase. The ability of BAF to
block acidification was validated by western blotting for a lysosomal protease
which matures only at low pH (Fig. 2.8). Measurements of CPS showed no
difference in total bacterial uptake (Fig. 2.7C) or the amount of capsule in
the cytosol (Fig. 2.7D) between macrophages treated with BAF and untreated
BMMs. These results show that cytosolic access of pneumococcal components
is independent of phagosome acidification.
P38 mitogen-activated protein kinase (MAPK) is an important factor in
host defense against diverse bacterial pore-forming toxins (116, 118, 195)
and is activated in a pneumolysin-dependent manner in both epithelial cells
(223) and macrophages (58). To investigate whether p38 MAPK detection of
pneumolysin affects cytosolic access, we treated BMMs with SB203580, an
inhibitor

of

p38

MAPK

activation

(MAPKi),

before

infection

with

S.

pneumoniae and sub-cellular fractionation. When p38 MAPK was inhibited in
BMMs infected with wild type (WT) S. pneumoniae, we observed a significant
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increase in the amount of CPS in the cytosol fraction (Fig. 2.9B), but no
change in total capsule in the whole-cell fraction (Fig. 2.9A). Infection of
MAPKi treated BMMs with the ply- strain showed no such increase in cytosolic
CPS amounts, demonstrating that the hypersensitization observed during
p38 MAPK inhibition is dependent on bacterial expression of pneumolysin
(Fig. 2.9B). These results suggest that pneumolysin dependent activation of
p38 MAPK limits the amount of pneumococcal CPS that accesses the cytosol
during infection.

Cytosolic access results in macrophage death
The final fate of host cells following infection with S. pneumoniae was
ascertained by incubating BMMs with a lysozyme sensitive (pgdA-/adr-)
bacterial strain expressing pneumolysin or an isogenic ply- strain (pgdA-/adr/ply-), in the presence or absence of CytD, and measuring cytotoxicity by
release of lactate dehydrogenase (LDH) at 24 hours after infection. BMMs
infected with the pneumolysin-expressing mutant had significantly higher
levels of cytotoxicity compared to BMMs infected with the isogenic ply- strain
or those treated with CytD (Fig. 2.10A). These results were also observed
upon infection of BMMs with the WT and its isogenic ply- bacterial strains
(Fig. 2.10B). Addition of the p38 MAPK inhibitor prior to infection did not
significantly alter macrophage cytotoxicity at 24 hours post-infection (Fig.
2.11).

These

data

show

that

macrophage

death

occurs

following

pneumococcal infection and is dependent on bacterial uptake and expression
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of pneumolysin.
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Discussion
Many Gram-positive pathogens express members of the CDC family, or
other pore-forming toxins (265). These toxins have diverse functions
including translocation of effectors by, for example, streptolysin O of
Streptococcus pyogenes (160), or access to a replicative niche, as in the case
of listeriolysin O (LLO) of Listeria monocytogenes (216). Unlike LLO, which
allows viable bacteria to access the cytosol of host cells, for S. pneumoniae,
it is bacterial contents following degradation and killing that transit into the
cytosol.
We (60) and others (115) have previously characterized Nod2dependent intracellular sensing of extracellular pathogens. In this study, we
adapted a sub-cellular fractionation assay, coupled with detection of CPS by
ELISA, to elucidate the mechanism by which cell wall components of the
extracellular bacterium, S. pneumoniae, escape into the host cell cytosol.
Here we visually and quantitatively demonstrate the transit of pneumococcal
products in a manner that is dependent on lysozyme, bacterial uptake,
pneumolysin, and specifically the ability of pneumolysin to bind and form
pores in host membranes. Our results suggest a model in which S.
pneumoniae is phagocytosed and degraded in the phagosome by lysozyme,
which results in release of the pore-forming toxin pneumolysin and allows
transit of bacterial components across the phagosome membrane to the
cytosol where they can be detected by intracellular host receptors. Others
have recently observed phagosome disruption at a later time-point post-
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infection, which is independent of pore-formation by pneumolysin (25),
suggesting that there may be more than one mechanism of accessing the
host cell cytosol.
Lysozyme is abundantly expressed on both the mucosal surface (49)
and within professional phagocytes (75). As a result, mucosal pathogens,
including S. pneumoniae and L. monocytogenes, modify their peptidoglycan
to confer increased resistance to this degradative enzyme (59, 220).
However,

these

modifications

confer

only

partial

resistance

because,

complementary to previously observed in vitro data (59), pneumococcal
killing by macrophages ex vivo is dependent on lysozyme, and modification
to the bacterial cell wall delays, but does not block, bacterial killing. Our
observation that cytosolic access does not require acidification of the
phagosome

is

consistent

with

lysozyme-dependent

pneumococcal

degradation, which can occur in broth culture at a neutral pH (59).
Previous work has characterized a role for pneumolysin in the transit
of other bacterial species’ peptidoglycan across the plasma membrane of
epithelial cells (222). While it is possible that lysed extracellular pneumococci
could access the host cytosol in a similar fashion, our finding that access to
the

cytosol in

professional phagocytes

requires

bacterial uptake

and

degradation suggests that the transit of pneumococcal cell wall components
we observe occurs across the phagosome membrane, rather than the plasma
membrane. Although we have not directly visualized bacterial contents
passing through the pore made by pneumolysin, our results demonstrate
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that the presence of pneumococcal products in the cytosol requires both
toxin expression and function.
P38 MAPK senses a diversity of bacterial toxins including proaerolysin
(116) and streptolysin O (223), a cytolysin in the same toxin family as
pneumolysin, and plays an important role in host defense. Activation of p38
MAPK occurs rapidly upon incubation of S. pneumoniae with macrophages
(58), making it likely that initial sensing occurs at the plasma membrane
prior to phagocytosis. Furthermore, purified pneumolysin is able to activate
p38 MAPK (223) suggesting that detection of toxin activity is independent of
host pattern recognition receptors present at the plasma membrane. Our
data show that host cell sensing of pneumolysin by p38 MAPK is able to limit
the transit of bacterial components to the cytosol, raising the possibility that
MAPK activation may attenuate phagosomal damage. Similar observations
have been made for Staphylococcus aureus α-toxin, in which p38 MAPK
activation is required for cellular recovery, presumably through plasma
membrane resealing (118). Lysosomal proteases have been shown to cleave
pneumolysin (40), raising the possibility that host proteolysis of this poreforming toxin may be another mechanism to limit cytosolic access. Ultimately
in the case of S. pneumoniae, these defenses are insufficient and cytosolic
access proves fatal for the host cell.
The observation that host cell death is dependent on bacterial uptake
and pneumolysin raises the possibility that accessing the cytosol evolved as a
mechanism to ensure death of the host cell that takes up the organism. In
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the

context

of

nasopharyngeal

colonization,

this

may

allow

the

pneumococcus to persist by limiting further clearance by the phagocytes that
are killed. However, accessing the host cell cytosol results in Nod2dependent pro-inflammatory signaling, leading to further recruitment of
phagocytic cells that aid in bacterial clearance. In addition to Nod2, S.
pneumoniae is known to activate type I interferon signaling pathways (208)
and the cytosolic NLRP3 and AIM2 inflammasomes (72) though strain-tostrain variation has been observed (282). In these studies host cell death
was dependent on both pneumolysin expression and bacterial uptake,
making it likely that the cell death observed in our study is a result of
inflammasome

activation.

Toxin-dependent

activation

of

the

NLRP3

inflammasome and subsequent phagocyte death has also been described for
other

extracellular

pathogens

(97).

While

inflammasome

signaling

is

important for host defense against pneumococcal pneumonia (72, 128, 282),
the role of inflammatory cytokines such as IL-1β in nasopharyngeal
colonization of S. pneumoniae remains to be defined.
Intracellular bacterial pathogens access the cytosol as part of their
lifecycle through use of pore-forming toxins or specialized secretion systems
(268). These virulence activities, however, expose pathogen associated
molecular patterns to host receptors. Here we show that components of S.
pneumoniae, a leading extracellular pathogen, access the cytosol via its
pore-forming toxin, pneumolysin, following degradation and killing in the
phagosome. Our results provide an example for how cytosolic access, and
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subsequent intracellular innate immune detection, is relevant to a clinically
important extracellular microbe.
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Figure 2.1. Pneumococcal cell wall components access the cytosol of
macrophages
(A) Murine bone marrow derived macrophages (BMMs) were incubated with
S. pneumoniae for 2.5 hours and stained for immunofluorescence with
polyclonal anti-type 23F capsule sera (red, capsule), anti-Lamp1 antibody
(green, phagosome), and DAPI (blue, DNA).
(B and C) Electron microscopy of BMMs incubated with S. pneumoniae for 45
minutes and immuno-gold labeled with IgG purified from polyclonal anti-type
23F capsule sera. Original magnification, x600 (A), x25,000 (B), and x50,000
(C).
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Figure 2.2. Pneumococcal cell wall components access the cytosol of
macrophages
(A and B) Electron microscopy of BMMs incubated with S. pneumoniae for 3
hours and immuno-gold labeled with IgG purified from polyclonal anti-type
23F capsule sera. White arrows indicate gold-particles outside of organelles.
Original magnification x15,000 (A) and x50,000 (B).
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Figure 2.3. Quantification of pneumococcal products by cellular
fractionation
(A) Western blot of sub-cellular fractions from bone marrow-derived
macrophages (BMMs) detecting cytosolic (LDH) and lysosome (Cathepsin B)
protein.
(B and C) Measurement of contents of cytosol fractions as a proportion of
whole cell contents by ELISA. Purity of fractions was measured by Cathepsin
B ELISA with dashed line indicating average level of contamination of
cytosolic fractions. Quantification of capsular polysaccharide (CPS) in the
cytosolic fractions (B) or whole cell fractions (C) of BMMs infected with wild
type (WT) or lysozyme hypersensitive (pgdA-/adr-) S. pneumoniae. Values
from 2-5 independent experiments, error bars represent ± SEM, One-way
ANOVA with Newman-Keuls post test, *p < 0.05, ***p < 0.001; and ns, not
significant.
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Figure 2.3 Continued.
(D and E) Gentamicin protection assay to measure intracellular killing of S.
pneumoniae (Spn). BMMs were infected with Spn and treated with 300
µg/mL gentamicin to kill extracellular bacteria. At the time points indicated,
BMMs were lysed with water and serial dilutions plated for CFUs to quantify
surviving Spn. C57BL/6 BMMs were infected with WT or pgdA-/adr- Spn
strains (D) and BMMs from FVB/N or LysM-/- mice were infected with the
lysozyme sensitive pgdA-/adr- Spn strain (E). Percentages were calculated as
a proportion of CFUs from the 5 min time point, values from 2 independent
experiments, error bars represent ± SEM, One-way ANOVA with NewmanKeuls post test, *p < 0.05, ***p < 0.001; and ns, not significant.
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Figure 2.4. Access to the cytosol is dependent on bacterial uptake
(A and B) Measurement of pneumococcal capsular polysaccharide in whole
cell (A) and cytosol (B) fractions of bone marrow derived macrophages
(BMMs) by ELISA. Where indicated, BMMs were infected with lysozyme
sensitive S. pneumoniae (Spn) and treated with 20 µM cytochalasin D (CytD)
to block phagocytosis. In contrast to other figures, cytosolic fractions are not
represented as a proportion of the whole fractions due to nearly undetectable
levels of capsule in the CytD treated whole cell fractions. Values from 3
independent experiments, error bars represent ± SEM, One-way ANOVA with
Newman-Keuls post test, *p < 0.05, ***p < 0.001.
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B

A

C

Figure 2.5. Pneumolysin is required for access to the host cell cytosol
(A and B) Measurement of pneumococcal capsule in whole cell (A) and
cytosol (B) fractions of bone marrow derived macrophages (BMMs) by ELISA.
Where indicated, BMMs were infected with S. pneumoniae strains with wild
type (WT) pneumolysin (Ply), complete deletion of the Ply gene (ply-), a
toxoid Ply unable to bind cholesterol (plyTL AA), and reintroduction of the full
WT Ply gene (ply+). Dashed line indicates average level of contamination of
cytosolic fractions (B). Values from 3-5 independent experiments, error bars
represent ± SEM, One-way ANOVA with Newman-Keuls post test, *p < 0.05.
→
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Figure 2.5 Continued.
(C) Gentamicin protection assay to measure intracellular killing of S.
pneumoniae (Spn). BMMs were infected with lysozyme sensitive S.
pneumoniae strains either deficient for pneumolysin (ply-) or expressing wild
type (WT) pneumolysin. BMMs were treated with 300 µg/mL gentamicin to
kill extracellular bacteria and at the time points indicated, were lysed with
water and serial dilutions plated for CFUs to quantify surviving Spn.
Percentages were calculated as a proportion of CFUs from the 5 min time
point, values from 2 independent experiments, Student’s t-test, ns, not
significant.
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plyplyTL→AA
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Figure
2.6. Validation
of
pneumococcal strains
expressing
pneumolysin mutations
(A) Hemolysis assay to test for pneumolysin pore-formation. Horse red blood
cells (RBC) were incubated with serially diluted lysates from S. pneumoniae
expressing wild type (WT) pneumolysin, a pneumolysin-deficient strain (ply), a toxoid that is unable to bind cholesterol (plyTL→AA), or a corrected mutant
strain (ply+), for 30 min. Lysis buffer alone was used as a negative control
(NC). Unlysed RBCs were pelleted and imaged. Representative images shown.
(B) Western blot for pneumolysin expression. Lysates from lysozyme
sensitive S. pneumoniae strains were probed for expression of pneumolysin
(Ply) or pneumococcal surface protein A (PspA) as a loading control.
Representative images shown.
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A

B

C

D

Figure 2.7. Cytosolic access is independent of TLR4 and acidification
(A and B) Bone marrow-derived macrophages (BMMs) from C57BL/6 (WT)
and Tlr4-/- mice were infected with S. pneumoniae and fractionated. Bacterial
capsular polysaccharide (CPS) in the whole cell (A) and cytosol (B) fractions
was measured by ELISA.
(C and D) BMMs from WT mice were treated with 30 nM bafilomycin A (BAF)
prior to infection with S. pneumoniae and sub-cellular fractionation. CPS in
the whole cell (C) and cytosol (D) fractions was measured by ELISA. Values
from 3 independent experiments, error bars represent ± SEM, Unpaired ttest, ns, not significant.
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Figure 2.8. Inhibition of phagosome acidification by bafilomycin A
treatment
(A) Whole cell fractions from S. pneumoniae infected macrophages untreated
or pre-treated with 30 nM bafilomycin A (BAF) for 1 hour were probed for the
lysosomal protein Cathepsin B or the cytosolic protein lactate dehydrogenase
(LDH). Images from same blot in non-contiguous lanes.
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B

A

Figure 2.9. Cytosolic access is attenuated by p38 MAPK activation
(A and B) BMMs were infected with a S. pneumoniae strains expressing
pneumolysin (WT) or a pneumolysin-deficient pneumococcal strain (ply-).
Where indicated, BMMs were treated with SB203580, a specific inhibitor of
p38 MAPK (MAPKi). Infected BMMs were fractionated and CPS was quantified
by ELISA in the whole cell (A) and cytosol (B) fractions, dashed line indicates
average level of contamination of cytosolic fractions. Values from 3-5
independent experiments, error bars represent ± SEM, One-way ANOVA with
Newman-Keuls post test, **p < 0.01***p < 0.001.
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Figure 2.10. Cytosolic access results in macrophage death
(A-B) Bone marrow-derived macrophages (BMMs) were infected with S.
pneumoniae strains or left uninfected (Un). Where indicated, BMMs were
treated with 20 µM cytochalasinD (CytD) to block phagocytosis. Supernatants
were collected at 24 hours post infection. Cytotoxicity was measured by
release of lactate dehydrogenase (LDH) in supernatants. BMMs were infected
with a lysozyme sensitive (pgdA-/adr-) and an isogenic pneumolysin deficient
(pgdA-/adr-/ply-) (A) or wild type (WT) and pneumolysin deficient (ply-)
strains (B). Values are from 2-4 independent experiments, error bars
represent ± SEM, One-way ANOVA with Newman-Keuls post test, ***p <
0.001, ND, not detected.
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Figure 2.11. Late macrophage death is not affected by prior p38
MAPK inhibition.
(A) Bone marrow-derived macrophages (BMMs) were infected with wild type
(WT) or pneumolysin-deficient (ply-) S. pneumoniae strains or left uninfected
(Un). Where indicated, BMMs were treated with SB203580, a specific
inhibitor of p38 MAPK (MAPKi). Supernatants were collected at 24 hours
post-infection and cytotoxicity was measured by release of lactate
dehydrogenase (LDH). Values are from 2 independent experiments, error
bars represent ± SEM, One-way ANOVA with Newman-Keuls post test, ***p <
0.001, ND, not detected.
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CHAPTER III

Sensing of IL-1 cytokines during Streptococcus pneumoniae
colonization contributes to macrophage recruitment
and bacterial clearance

The contents of this chapter were submitted to: Infection and Immunity
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Abstract
Streptococcus pneumoniae, a leading cause of bacterial disease, is
most commonly carried in the human nasopharynx. Colonization induces
inflammation that promotes the organism’s growth and transmission. This
inflammatory response is dependent on intracellular sensing of bacterial
components, which access the cytosolic compartment via the pneumococcal
pore-forming toxin pneumolysin. In vitro, cytosolic access results in cell
death that includes release of the pro-inflammatory cytokine IL-1β. IL-1
family

cytokines,

including

IL-1β,

are

secreted

upon

activation

of

inflammasomes, though the role of this activation in the host immune
response to pneumococcal carriage is unknown. Using a murine model of
pneumococcal nasopharyngeal colonization, we show that mice deficient in
the interleukin-1 receptor type 1 (Il1r1-/-) have reduced numbers of
neutrophils early after infection, fewer macrophages later in carriage, and
prolonged bacterial colonization. Moreover, intranasal administration of Il-1β
promoted clearance. Macrophages are the effectors of clearance and
characterization of macrophage chemokines in colonized mice revealed that
Il1r1-/- mice have lower expression of the C-C motif chemokine ligand 6
(CCL6),

correlating

nasopharynx.

IL-1

with
family

reduced

macrophage

cytokines

are

known

recruitment
to

promote

to

the

adaptive

immunity. However, we observed no difference in the development of
humoral or cellular immunity to pneumococcal colonization between wild type
and Il1r1-/- mice. Our findings show that sensing of IL-1 cytokines during
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colonization promotes inflammation without immunity, which may ultimately
benefit the pneumococcus.
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Introduction
Streptococcus pneumoniae is an opportunistic bacterial pathogen that
is responsible for over 1 million deaths annually, mostly in children under the
age of five (283). The pneumococcus serially colonizes the mucosal surfaces
of the human upper respiratory tract, and carriage of the organism provides
the reservoir for all pneumococcal disease (29). Colonization induces airway
inflammation that is characterized by a suppurative rhinitis and increased
mucus secretion.

These secretions promote bacterial growth (247) and

inflammation is important for bacterial transmission in a viral co-infection
model (244). Human studies have demonstrated that higher bacterial
burdens are correlated with a more profound rhinitis (234). However, as a
result of this inflammatory response, colonization is normally cleared by the
host immune system within several weeks (173).
A well-defined murine model of pneumococcal colonization (174) has
elucidated bacterial and host factors that are critical to immune recognition
of the pneumococcus, which drives the eventual resolution of the carrier
state. Although early colonization triggers the recruitment of neutrophils,
these are ineffective at resolving the infection. Clearance of pneumococci
from the upper airway over a period of weeks requires a sustained presence
of macrophages in the nasopharynx (291). Although S. pneumoniae is an
extracellular pathogen, this macrophage influx is the result of intracellular
innate immune recognition by the cytosolic receptor Nod2 (60). Nod2 detects
peptidoglycan (88, 259) that accesses the macrophage cytosol via the
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pneumococcal pore-forming toxin, pneumolysin, following phagocytosis and
bacterial degradation (151). Nod2 activation results in nuclear factor κB
activation (203) and drives production of pro-inflammatory cytokines, such
as

CCL2,

which

contributes

to

macrophage

dependent

pneumococcal

clearance (60). Cytosolic access, however, is a fatal event for the host cell
following bacterial uptake (151). The type of cell death that occurs and its
contribution to the host immune response remains unclear.
Our further in vitro studies show that macrophage death results in
pneumolysin-dependent release of the pro-inflammatory cytokine IL-1β,
indicating activation of the inflammasome. Inflammasomes are multi-protein
cytosolic complexes that oligomerize through homotypic domain interactions
and are comprised of a sensor, which detects bacterial stimuli, and adaptor
proteins that recruit procaspase-1. This recruitment drives caspase-1
enzymatic activation, which processes pro-IL-1β and pro-IL-18 into their
mature forms and results in a pro-inflammatory cell death known as
‘pyroptosis’ (51).
The role of inflammasome activation and the production of IL-1 family
cytokines in pneumococcal disease has been characterized (72, 128, 133,
175). However, carriage rather than disease is the predominant state for
pneumococci in the host. The contribution of pro-inflammatory cell death to
immunity against this extracellular pathogen during colonization has not
been determined. Here we show that host sensing of IL-1 family cytokines in
vivo is required for the macrophage presence in the nasopharynx and
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clearance of pneumococcal colonization. IL-1 cytokine production in response
to the pneumococcus contributes to inflammation in the upper airway,
without driving the eventual development of adaptive immune responses.
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Results
Pneumococcal infection results in IL-1 family cytokine expression in vitro and
in vivo
We have previously reported that infection of macrophages with a type
23F strain of S. pneumoniae results in host cell death, subsequent to
bacterial

uptake

pneumococcal

and

fragments

pneumolysin-dependent
(151).

To

determine

cytosolic
whether

access

of

pneumolysin-

dependent cytosolic access causes pro-inflammatory cytokine release upon in
vitro infection, we incubated BMMs with the wild type 23F isolate (WT) and
24 hours later assayed for the presence of IL-1β in the cell culture
supernatants by Western blotting. We observed the release of mature IL-1β
by BMMs infected with WT bacteria, but not in the supernatants of BMMs
infected with an isogenic pneumolysin-deficient strain (ply-) (Fig. 3.1A).
Furthermore, pre-incubation with CytD, an inhibitor of actin polymerization
reduced the amount of IL-1β secreted, suggesting that pro-inflammatory
cytokine production is dependent on bacterial uptake. Quantification by
ELISA showed that release of IL-1β by BMMs was significantly reduced during
infection with the ply- strain and when phagocytosis was blocked by CytD
treatment (Fig. 3.1B). Additionally, enzymatic processing of caspase-1 and
production of its active p10 fragment correlated with secretion of IL-1β (Fig.
3.1A). These results show that following infection with a WT pneumococcal
strain, BMMs release the pro-inflammatory cytokine IL-1β and that this is
dependent on bacterial uptake and expression of the pneumococcal pore-
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forming toxin.
To ascertain whether IL-1 family cytokines are expressed in vivo
during pneumococcal colonization, mice were intranasally inoculated with the
WT S. pneumoniae strain. Cytokine levels could not be detected because the
airway surface fluid is highly diluted in lavages from the upper respiratory
tract. Therefore, lysates of the respiratory epithelium were obtained and
quantitative RT-PCR (qRT-PCR) preformed to assess Il1a (Fig. 3.2A) and Il1b
(Fig. 3.2B) gene expression. We observed that upon colonization with S.
pneumoniae (Spn) Il1b (Fig. 3.2B) was significantly up-regulated compared
to mock colonized mice. A much smaller but significant increase in Il1a (Fig.
3.2A) expression was observed. Inflammasome components, including proIL-1β, are up-regulated upon TLR signaling and this ‘priming’ provides the
first signal required for inflammasome activation (16, 38, 129). Previous
studies

of

inflammasome

activation

and

IL-1β

release

following

pneumococcal infection in vitro have characterized TLR2 dependent IL-1β
secretion (282). To determine the role of TLR2 in the up-regulation of Il1a
and Il1b gene transcripts during pneumococcal colonization, we inoculated
TLR2-deficient (Tlr2-/-) mice with WT Spn, obtained lysates of the epithelial
tissue, and performed qRT-PCR to measure Il1a and Il1b transcription. We
found that Tlr2-/- mice had no significant up-regulation of Il1a (Fig. 3.2C) or
Il1b (Fig. 3.2D), demonstrating that the increased expression of both genes
in vivo is dependent on TLR2.
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Sensing of IL-1 cytokines is required for inflammation and macrophage
driven bacterial clearance
The role of IL-1 sensing in early events in pneumococcal colonization
was investigated by inoculating wild type (WT) and type 1 IL-1 receptor
deficient (Il1r1-/-) mice with S. pneumoniae and obtaining PBS lavages of the
upper respiratory tract at 3 days post-infection. We assessed bacterial
burden and host immune cell infiltrates by plating for colonizing pneumococci
and flow cytometry, respectively. We observed no significant difference in
bacterial numbers in the nasopharynx (Fig. 3.3A), however, there were
significantly lower numbers of neutrophils in lavages from the Il1r1-/- mice
compared to WT mice (Fig. 3.3B). Macrophage numbers were low, consistent
with previous studies (60, 291), and there was no significant difference
between the two groups (Fig. 3.3C). These results suggest that Il1r1-/- mice
have

a

dampened

early

inflammatory

response

to

S.

pneumoniae

colonization.
To address the role of IL-1 sensing in subsequent clearance of
colonization, WT and Il1r1-/- mice were inoculated with S. pneumoniae and
bacterial counts and cellular infiltrates were quantified at 14 days postinfection. We observed that WT mice had a significantly lower bacterial load
compared to day 3 post-infection (Fig. 3.3A), indicating a partial clearance of
pneumococcal colonization. In contrast, Il1r1-/- mice had no difference in
bacterial numbers between days 3 and 14 post-colonization (Fig. 3.3A).
Additionally, two weeks after inoculation there was a significantly higher
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bacterial burden in the Il1r1-/- mice compared to WT (Fig. 3.3A). There were
similar quantities of neutrophils present in the nasopharynx (Fig. 3.3D) of WT
and Il1r1-/- mice. However, the numbers of macrophages, the effectors of
pneumococcal clearance (291), were significantly decreased in the Il1r1-/group (Fig. 3.3E). This attenuated clearance and delayed macrophage
recruitment resembles previous findings in Tlr2-/- mice and WT mice
colonized with a pneumolysin-deficient mutant (267, 291), both factors
implicated in inflammasome activation. From these findings we conclude that
sensing by the IL-1 receptor is required for increased macrophage presence
in the nasopharynx and clearance of pneumococci.
The contribution of IL-1β to clearance of pneumococci from the
nasopharynx was assessed by administration of recombinant cytokine after
colonization with a pneumolysin-deficient S. pneumoniae strain. This strain
was used to minimize endogenous production of cytokine. Following the
establishment of colonization, the mice were intranasally dosed with a low
(100 ng) or high (200 ng) amount of IL-1β every other day. At 14 days postinfection PBS lavages of the respiratory tract were obtained and bacterial
quantity was measured. We observed a significant dose-dependent decrease
in bacterial numbers when mice received intranasal IL-1β (Fig. 3.3F). This
suggests that IL-1β is sufficient to promote clearance of pneumococcal
colonization.

Il1r1-/- mice have altered macrophage chemokine expression
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Previous studies investigating clearance of pneumococcal colonization
have characterized an essential role for the host C-C chemokine receptor
CCR2 in macrophage recruitment and retention in the nasopharynx (60).
CCR2 binds multiple ligands in the C-C motif chemokine family, that act as
macrophage attractants (170). To assess the role of IL-1 sensing in
macrophage recruitment to the nasopharynx we investigated the expression
of several CCR2 ligands during pneumococcal colonization. WT and Il1r1-/mice were inoculated with S. pneumoniae and at days 3 and 14 postcolonization

we

obtained

lysates

of

the

upper

respiratory

tract

and

determined chemokine expression by qRT-PCR. We observed no significant
difference between WT and Il1r1-/- mice in expression of any CCR2 ligand at
day 3 post-inoculation (Fig. 3.4A). At day 14 post-infection, when clearance
had initiated, Il1r1-/- mice had significantly lower expression of Ccl6
compared to WT mice (Fig. 3.4B). These findings demonstrate that Il1r1-/mice have an altered macrophage chemokine profile, which includes a
reduction in CCL6 expression that correlates with lower macrophage
presence and delayed clearance.

Il1r1-/- mice do not have altered adaptive immunity to the pneumococcus
Although there is a contribution of type-specific antibody to protection
induced by either vaccination or prior exposure (55, 163), effective clearance
of primary colonization requires Th17-dependent cellular immunity rather
than humoral responses (157, 291). Il-1β is a known driver of Th17
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responses

(46),

which

contribute

to

macrophage

recruitment

during

colonization (291). We investigated this potential role of IL-1 sensing in cellmediated immunity by comparing expression of Il17a in WT and Il1r1-/colonized mice by qRT-PCR. We observed no significant difference in Il17a
transcription between the WT and Il1r1-/- mice (Fig. 3.5A). To address a
possible effect on humoral immunity, we measured the geometric mean titer
(GMT) of whole anti-pneumococcal serum IgG from WT and Il1r1-/- colonized
mice. Both groups had detectable antibody titers, though there was no
significant difference in GMT (Fig. 3.5B). The development of adaptive
immunity to the pneumococcus was interrogated using a secondary challenge
model. WT and Il1r1-/- mice were colonized with S. pneumoniae and allowed
to clear for a period of 8 weeks. The mice were then re-challenged with a
marked isogenic strain that could be distinguished from the primary
challenge strain and at day 4 post-colonization nasal lavages were obtained
and bacterial quantity measured. Compared to the bacterial burden observed
at day 3 during primary colonization, WT mice had significantly lower CFUs in
the nasopharynx upon secondary challenge (Fig. 3.5C). Similarly, the Il1r1-/mice also exhibited a significant drop in bacterial levels upon secondary
colonization of an immune host (Fig. 3.5C). Together these data show that
signaling through the IL-1 receptor contributes to inflammation without
impacting adaptive immune responses to pneumococcal colonization.
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Discussion
Host

defense

against

S.

pneumoniae

requires

the

activity

of

professional phagocytes and previous studies have defined a critical role for
macrophages in the clearance of colonization (291). This macrophage
presence

in

the

nasopharynx

is driven

by

sensing

of pneumococcal

components that access the host cell cytosol through the action of the poreforming toxin pneumolysin (60, 151). Cytosolic access results in death of the
phagocytes that clear the organism. However, this appears to result in proinflammatory

cytokine

production,

mediated

by

activation

of

the

inflammasome, which further contributes to sustaining the inflammatory
response against the colonizing pneumococci.
Pneumococcal strains have been reported to vary in their ability to
activate inflammasome signaling (282), however our observation that
macrophages activate caspase-1 and secrete IL-1β following pneumococcal
infection aligns with previous studies that have reported similar findings in
other cell types with different pneumococcal strains (72, 133, 175). These
investigations have demonstrated a pneumolysin-dependent activation of
both the NLRP3 (133, 175) and AIM2 inflammasomes (72), which sense
membrane perturbations and cytosolic DNA respectively. While recombinant
pneumolysin alone, presumably acting at the plasma membrane, can activate
the NLRP3 inflammasome (175), caspase-1 maturation and IL-1β secretion
following infection with whole bacteria requires phagocytosis (72). This
suggests
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of

pneumolysin,

which

triggers

inflammasome formation, occurs at the phagosome membrane.
The NLRP3 receptor and ASC signaling adaptor protein have both been
implicated in defense against pneumococcal pneumonia (72, 175) and
corneal infection (133). However, nasopharyngeal colonization is the most
common

pneumococcal-host

interaction

and

until

now

the

role

of

inflammasome derived innate immune signaling during carriage has not been
addressed. While we have defined a critical role for sensing by the IL-1
receptor during of S. pneumoniae colonization, the specific IL-1 receptor
agonists that contribute to bacterial clearance remain to be defined.
Nevertheless, IL-1β is highly expressed during colonization and is sufficient
to reduce S. pneumoniae density.
Our observation that sensing of IL-1 family cytokines contributes to
inflammation

in

the

nasopharynx

following

pneumococcal

colonization

complements previous reports that IL-1β and IL-1 receptor signaling is
important for host defense against disease states caused by other mucosal
pathogens,

including

Staphylococcus

aureus

(117)

and

group

B

Streptococcus (GBS) (27). Both of these organisms trigger IL-1β secretion
through toxin-dependent activation of the inflammasome (97, 166), which
drives neutrophil activation and pro-inflammatory cytokine production that
controls infection (26, 189). The contribution of inflammasome signaling
during natural carriage of these organisms remains unexplored. Unlike S.
aureus or GBS, neutrophil responses are insufficient to clear S. pneumoniae
during infection (291) and IL-1β appears to contribute to the macrophage
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recruitment that promotes reduction in bacterial burden. The requirement for
IL-1 sensing in macrophage recruitment during bacterial infection is less well
understood. However, IL-1 sensing in the lung during fungal infection is
known

to

enhance

expression

of

both

neutrophil

and

macrophage

chemokines (39). Macrophage presence during pneumococcal colonization is
dependent on host expression of CCR2, which binds multiple ligands. We
observe that Il1r1-/- mice have diminished macrophage numbers in the
nasopharynx two weeks after pneumococcal colonization, which correlates
with significantly lower expression of CCL6.
CCL6 is a C-C motif chemokine originally indentified in murine bone
marrow (206). It acts as a macrophage chemoattractant (147) and is highly
expressed in peripheral eosinophils and elicited macrophages (147, 285), as
well as lung tissue (109, 132) and epithelial cells of the intestinal mucosa
(145). In addition to its chemokine functions, CCL6 may have intrinsic
antibacterial properties (145) and over expression of CCL6 in transgenic mice
confers protection against bacterial sepsis (48). Multiple studies have
observed that in contrast to CCL2, which is expressed early during
inflammation, CCL6 induction occurs later and is sustained for several days
to over a week (207, 285). These results, from a model of peritonitis,
suggest that CCL2 acts in initial macrophage recruitment and that CCL6
sustains macrophage presence. This raises the possibility that IL-1 cytokines,
generated as a result of pro-inflammatory macrophage death during
pneumococcal colonization, contribute to the chemokine production that

!

76!

sustains macrophage presence throughout the course of bacterial clearance.
Previous studies have defined an important role for the intracellular
receptor Nod2 in innate immune defense against pneumococci (60).
However, in these studies, a minimal clearance defect was observed in Nod2deficient mice, although mice lacking both Nod2 and TLR2 had a significantly
higher bacterial burden at a time point when WT mice had no bacterial
carriage. Combined with our observation that up-regulation of IL-1 cytokines
is dependent on TLR2, this suggests that cytosolic access of pneumococcal
components triggers two innate immune sensing pathways, both of which
contribute to the orchestrated immune response that clears colonization.
Activation of multiple sensing pathways may also be critical for controlling
pneumococcal disease. Patients deficient in MYD88 or IRAK-4, adaptor
proteins for both TLRs and the IL-1 receptor, are acutely susceptible to
recurrent

pneumococcal

sepsis

(21,

50,

146,

212,

213).

However,

polymorphisms in TLRs alone do not correlate with significant increases in S.
pneumoniae disease (182), suggesting that sensing by both TLRs and the IL1 receptor may be critical for host defense.
Although

pneumolysin-mediated

cytosolic

access

triggers

innate

immune responses that eventually clear S. pneumoniae, this may still be to
the benefit of the bacterium. Cytosolic access results in the death of the
phagocytes that clear the organism and generates IL-1 family cytokines that
drive inflammation, an important factor in both bacterial growth (247) and
transmission (244). Sensing of IL-1 cytokines, however, does not appear to
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contribute to the development of an adaptive immune response, suggesting
that toxin expression and cytosolic access drives IL-1 cytokine-mediated
inflammation that benefits the organism without inducing further immunity
that is detrimental to its persistence.
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Figure 3.1. Pneumococcal infection results in IL-1β release in vitro
(A and B) Bone marrow-derived macrophages (BMMs) were infected with wild
type (WT) or pneumolysin-deficient (ply-) S. pneumoniae strains or left
uninfected (Un). Where indicated, BMMs were treated with 20µM cytochalasin
D (CytD) to block phagocytosis. Supernatants were collected at 24 hours
post infection.
(A) Western blot of supernatants for the presence of caspase-1 (Casp-1) and
interleukin-1 beta (IL-1β). BMMs primed with 0.5 µg/mL LPS and stimulated
with ATP were used as a positive control (PC). Representative images shown.
(B) Amounts of IL-1β in supernatants were quantified by ELISA. Results are
from 2 independent experiments, error bars represent ± SEM, One-way
ANOVA with Newman-Keuls post test, ***P < 0.001.
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A"

B"

C"

D"

Figure 3.2. Expression of IL-1 cytokines is up-regulated during S.
pneumoniae colonization and is dependent on TLR2.
(A-D) Wild type (black bars) or TLR2-deficient (Tlr2-/-, white bars) mice were
intranasally inoculated with 107 CFU of S. pneumoniae (Spn). At 14 days
post-colonization the upper respiratory tracts were lavaged with RLT RNA
lysis buffer. Gene expression relative to PBS (Mock) inoculated mice was
measured by quantitative RT-PCR for Il1a (A and C) and Il1b (B and D).
Results are from at least 2 independent experiments, n > 10 mice, error bars
represent ± SEM, Mann-Whitney U test, *P < 0.05, ***P < 0.001, ns, not
significant.
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Figure 3.3. Sensing of IL-1 family cytokines is important for bacterial
clearance and macrophage recruitment.
(A-E) Wild type (WT, black) or IL-1 receptor-deficient (Il1r1-/-, grey) mice
were intranasally inoculated with 107 CFU of S. pneumoniae and at the timepoints indicated PBS lavages of the upper respiratory tract were obtained.
(A) Bacterial numbers of colonizing pneumococci were quantified by plating
of nasal lavages. Dashed line indicates limit of detection. Results are from 2
to 4 independent experiments, n ≥ 10 mice per group, error bars represent
± SEM, Kruskal-Wallis with Dunn’s post-test, **P < 0.01, ns, not significant.
(B-E) Cellular infiltrates in the nasal lavages of 5 mice were measured by
flow cytometry. Quantification of neutrophils
(Ly6G+, CD11b+) and
+
monocytes/macrophages (F4/80 , CD11b ) after 3 (B and C) and 14 (D and
E) days of colonization are shown. Results are from 4 independent
experiments, error bars represent ± SEM, Student’s t-test or Mann-Whitney
U test as appropriate, *P < 0.05, ns, not significant.
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Figure 3.3 Continued.
(F) WT mice were inoculated with 107 CFU of a pneumolysin-deficient S.
pneumoniae strain and intranasally administered 100 or 200 ng of
recombinant IL-1β (white circles) or vehicle control (PBS, black circles) every
other day for 14 days. Nasal lavages were obtained and numbers of
pneumococci were measured by plating serial dilutions. Dashed line indicates
limit of detection. Results are from 2 experiments, n ≥ 4 mice per group,
error bars represent ± SEM, Kruskal-Wallis with Dunn’s post-test, *P < 0.05.
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A"

B"

Figure 3.4. Il1r1-/- mice have altered C-C chemokine profiles during
S. pneumoniae colonization.
(A and B) Wild type (WT, black bars) or IL-1 receptor-deficient (Il1r1-/-, grey
bars) mice were inoculated with 107 CFU of S. pneumoniae. At 3 (A) and 14
(B) days post-colonization RLT RNA lysis buffer lavages of the upper
respiratory tract were obtained and gene expression of Ccl2, Ccl6, Ccl7, and
Ccl8 was measured by quantitative RT-PCR. Values are relative to PBS
(Mock) inoculated mice. Results are from 2 to 4 independent experiments, n
≥ 9 mice, error bars represent ± SEM, Mann-Whitney U test, *P < 0.05, **P
< 0.01, ns, not significant.

!

85!
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C"

Figure 3.5. Sensing of IL-1 does not alter adaptive immunity to the
pneumococcus.
(A and B) Wild type (WT, black bars) or IL-1 receptor-deficient (Il1r1-/-, grey
bars) mice were intranasally colonized with S. pneumoniae (Spn) for 14
days.
(A) RLT RNA lysis buffer lavages of the respiratory tract were obtained and
expression of Il17a was measured by quantitative RT-PCR. Values are
reported as fold-change relative to PBS (Mock) inoculated mice. Student’s ttest, ns, not significant.
(B) Total anti-pneumococcal serum IgG levels were measured by ELISA.
Values are expressed as geometric mean titer (GMT), Kruskal-Wallis with
Dunn’s post-test, ns, not significant.
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Figure 3.5 Continued.
(C) WT (black circles) or Il1r1-/- (grey circles) mice were inoculated with 107
CFU of S. pneumoniae. For primary (1°) colonization, mice were sacrificed at
day 3 post-colonization, PBS nasal lavages obtained, and bacterial density
measured by plating. For secondary (2°) colonization, mice were allowed 8
weeks to clear the pneumococci and then rechallenged with an isogenic S.
pneumoniae strain distinguishable by antibiotic resistance. Nasal lavages
were obtained at day 4 post-secondary colonization and bacterial density was
quantified by plating. Dashed line indicates limit of detection. Results are
from 2 to 5 independent experiments, n ≥ 10 mice, error bars represent ±
SEM, Kruskal-Wallis with Dunn’s post-test, **P < 0.01, ***P < 0.001.
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CHAPTER IV

Materials and Methods
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Bacterial Strains and Mutants
S. pneumoniae strains were grown overnight at 37°C on trypic soy (TS) agar
plates containing 5% sheep blood (BD) and the following day, liquid cultures
were inoculated into broth TS and incubated in a nonshaking water bath at
37°C to mid-log phase (OD≈0.5). The wild type 23F strain was originally
isolated from an experimental human carriage study (173). Mutations in
pgdA and adr (59) were introduced into previously described S. pneumoniae
strains that were either deficient in or corrected for pneumolysin expression
(60, 171) by transformation with chromosomal DNA, followed by selection for
kanamycin

(500

µg/mL)

and

spectinomycin

(200

µg/mL)

resistance,

respectively. Sensitivity to lysozyme was phenotypically confirmed by in vitro
bacterial lysis as previously described (59). The plyTL

→

AA

mutation, containing

previously characterized alanine mutations at the threonine and leucine
residues responsible for binding cholesterol (73),

was constructed using

overlap extension PCR with primer pairs to introduce the two alanine
mutations (Fwd 5’–TGG GGA ACA GCT GCC TAT CCT CAG GTA GAG GAT-3’
and Rev 5’-ATC CTC TAC CTG AGG ATA GGC AGC TGT TCC CCA-3’) and
primers flanking the pneumolysin gene (Fwd 5’-AAA AAA GAA GCC GAT AAG
GAA AAG ATG AGC G-3’ and Rev 5’-GAA AGT TTC AGC CAA GTT TGA CAA
AGT CAG CTC-3’). The amplified construct was introduced into a 23F
pneumococcal strain containing a Janus Cassette (253) in place of the
pneumolysin

gene

by

transformation

and

homologous

recombination.

Transformants were selected for streptomycin resistance (200 µg/mL) and
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sensitivity

to

kanamycin

(200

µg/mL)

was

confirmed

by

patching.

Pneumococci were pelleted by centrifugation at 14,000 rpm and resuspended
in phosphate buffered saline (PBS).

Hemolysis Assay
As previously described (223), pellets of wild type (WT), pneumolysindeficient (ply-), pneumolysin toxoid (plyTL

→

AA),

or corrected (ply+) S.

pneumoniae cultures were lysed in 400 µL lysis buffer (0.01% sodium
dodecyl sulfate, 0.1% sodium deoxycholate, and 0.015M sodium citrate) and
incubated at 37°C for 30 min. Lysates were then transferred to a 96-well Vbottom plate and serially diluted three fold in DTT buffer (10 mM
dithiothreitol, 0.1% bovine serum albumin in phosphate buffered saline). 2%
horse red blood cells were added to each well and incubated at 37°C for 30
min. Plates were centrifuged for 10 min at 3000 rpm to pellet unlysed cells
and imaged.

Cell Culture
Bone-marrow cells harvested from the femurs and tibiae of C57BL/6, FVB/N,
LysM-/-, and Tlr4-/- mice were differentiated into macrophages by culturing in
Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 30% L929
supernatant, and 20% FBS at 37°C with 5% CO2 for 7-9 days. One day prior
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to infection, macrophages were replated in DMEM supplemented with 15%
L929 enriched supernatant and 10% FBS. All animal experiments were
conducted

according

to

the

guidelines

outlined

by

National

Science

Foundation Animal Welfare Requirements and the Public Health Service Policy
on the Humane Care and Use of Laboratory Animals. The protocol was
approved by the Institutional Animal Care and Use Committee, University of
Pennsylvania Animal Welfare Assurance Number A3079-01, protocol number
803231.

Immunofluorescence Staining and Confocal Microscopy
BMMs were seeded on to poly-L lysine-coated coverslips (BD) in a 24-well
plate at a density of 2.5x105 cells/slip and the following day, were incubated
with non-opsonized pgdA-/adr- pneumococci at MOI=10 for 2.5 hours,
washed with PBS, and fixed in 3% paraformaldehyde. Cells were quenched
with 50 mM NH4Cl and permeabilized with PGS (0.01% saponin, 0.25%
gelatin, 0.02% sodium azide, in PBS). To detect pneumococcal capsular
polysaccharide, the cells were incubated with type 23F rabbit serum (Statens
Serum Institut) at a dilution of 1:5000 and detected with an anti-rabbit-Cy3
secondary antibody (Jackson ImmunoResearch) at a dilution of 1:600 in PGS.
Phagosome membranes were labeled with a rat anti-Lamp-1 antibody
(eBioscience) at a dilution of 1:500 in PGS and primary antibody was
detected with an anti-rat Cy2-conjugated secondary antibody (Jackson
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ImmunoResearch) at a dilution of 1:600 in PGS. Nuclei were stained with 0.5
ug/mL DAPI for 3 min. Slides were imaged on a Nikon Eclipse Ti-U spinning
disk confocal microscope at the Molecular Pathology and Imaging Core at the
University of Pennsylvania.

Electron Microscopy
Macrophage samples were high pressure frozen in an Abra HPM-010 and
freeze substituted in 99% acetone, 0.1% uranyl acetate, 1% dH2O in a Leica
AFSII. Freeze substitution was performed at -90°C for 72 hours and then
ramped to -50°C over 24 hours where cells were placed in four hour graded
steps of 25%, 50%, 75%, 100% HM-20 in acetone. HM-20 was polymerized
with 360 nm light for 48 hrs at -50°C and an additional 24 hours at room
temperature. Polymerized blocks trimmed to regions of interest were cut at
60-80 nm thickness and immunologically probed with IgG purified type 23F
rabbit serum. Protein A conjugated to 15 nm colloidal gold was used to
secondarily detect the presence of antibody-antigen complexes. Imaging was
performed on a JEOL 1010 TEM operating at 80 KeV.

Cellular Fractionation
BMMs were seeded in a 6-well, non-tissue culture-treated plate at a density
of 1x106 cells/well. The following day, the cells were infected with non-
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opsonized pneumococcal strains at MOI=50 and spun for 5 min at 3000 rpm.
Where indicated, the BMMs were incubated with 20 µM cytochalasin D
(Sigma), 30 nM bafilomycin A, (Sigma) or 10 µM SB203580 (Cell Signaling)
at 37°C for 1 hour prior to infection. Following infection, the cells were
incubated on ice for 1 hour, washed five times with PBS, and incubated for
an additional 2 hours at 37°C. BMMs were washed three times with PBS,
lifted with PBS containing 2 mM EDTA and permeabilized in 20 µM digitonin
(Sigma) to lyse the plasma membrane to generate cytosol fractions, or 0.1%
saponin (Fluka) to lyse all membranes to generate whole cell fractions. Cells
were spun at 15,000 g for 10 min and the resulting supernatants were
ultracentrifuged at 4°C for 1 hour at 355,000 g. Supernatants were
lyophilized and resuspended in dH2O.

Gentamicin Protection Assay
BMMs were seeded in a 12-well plate at a density of 4x105 cells/well and, the
following day, infected with pneumococcal strains at MOI=50 and spun for 5
min at 3000 rpm. The BMMs were incubated on ice for 1 hour, then washed
three times with PBS, and incubated at 37°C for 15 min for bacterial uptake.
300 µg/ml gentamicin was then added to kill remaining extracellular bacteria.
At the time points indicated, the cells were lysed with dH2O and serially
diluted in PBS. Dilutions were plated on TS agar plates and incubated
overnight at 37°C/5% CO2.
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Cytotoxicity Assay
BMMs were seeded in a 48-well plate at a density of 2.5x105 cells/well and
cultured overnight at 37°C. The following day the cells were primed with 400
ng/mL Pam3CSK4 for 4 hours and then infected with S. pneumoniae at
MOI=10. At 2 hours post-infection the cell culture medium was replaced with
DMEM containing 300 µg/mL gentamicin. Supernatnants from infected
macrophages

were

collected

at

24

hours

post-infection.

Lactate

dehydrogenase release was quantified using the Cytotoxicity Detection Kit
Plus (Roche) per the instructions of the manufacturer.

ELISA for IL-1β
Supernatants harvested at 24 hours post-infection were assayed for the
presence of IL-1β using the ELISA MAX Mouse IL-1β Kit (BioLegend) per the
instructions of the manufacturer.

Western Blotting
Supernatants from BMMs infected with pneumococci were harvested at 24
hours post-infection, separated on a 10% Tris-SDS gel (BioRad) and detected
by primary antibody incubation for Caspase-1 (Santa Cruz) at a dilution of
1:200 and IL-1 beta (AbCam) at a dlution of 1:2000. Sub-cellular fractions
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from BMMs were validated by running resuspended supernatants on a 10%
Tris-SDS

gel

(BioRad).

Monoclonal

anti-Lactate

dehydrogenase

and

polyclonal anti-Cathepsin B antibodies (AbCam) were used for primary
detection. Lysates from S. pneumoniae strains expressing pneumolysin
mutations were separated on a 10% Tris-SDS gel and detected using a
mouse monoclonal anti-pneumolysin primary antibody (Leica) and previously
described (57) anti-pneumococcal surface protein A (PspA) mouse serum.
Rabbit horseradish peroxidase (HRP) conjugated (GE Healthcare) and mouse
HRP conjugated (GE Healthcare) antibodies were used for detection of the
primary antibodies.

ELISA for Capsular Polysaccharide
Sub-cellular fractions of infected BMMs were assayed for pneumococcal CPS
by capture ELISA. Immulon 2HB plates (Thermo Scientific) were coated with
type 23F rabbit serum at a dilution of 1:5000 and incubated overnight at
room temperature (RT). The plate was incubated with serial dilutions of
samples or a type 23F CPS standard (ATCC) for 2 hours at RT. Samples and
standards were detected with a monoclonal anti-23F CPS antibody at a 1:300
dilution for 2 hours at RT. Monoclonal antibody was detected with a goat
anti-mouse alkaline phosphotase antibody (Sigma) at a 1:10000 dilution for
2 hours at RT. The plate was developed with phosphatase substrate (Sigma)
for 30 min and read at OD=415nm.
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Murine Model of S. pneumoniae Nasopharyngeal Colonization
C57BL/6 (WT) and Tlr2-/- mice were obtained from The Jackson Laboratory.
Il1r1-/- mice (89) were a generous gift from Sunny Shin (University of
Pennsylvania). 107 colony forming units (CFU) of S. pneumoniae in 10 µL PBS
were inoculated into the nares of unanesthetized mice. Inocula were serially
diluted in PBS and grown overnight on TS agar plates to verify dose. At the
time points indicated in the figures, the mice were sacrificed, the trachea
cannulated, and lavaged with 200 µL PBS through the nares. The resulting
lavage fluid was plated in serial dilutions on TS agar plates, grown overnight
at 37°C/5% CO2, and the following day CFU counted. For intranasal
administration of cytokine, WT mice colonized with a pneumolysin-deficient
S. pneumoniae strain (222) received 100 or 200 ng of recombinant IL-1β
(eBioscience) resuspended in 10 µL PBS or 10 µL PBS alone as a vehicle
control every other day for 14 days. For secondary challenge experiments,
mice of the indicated genotype were colonized with WT S. pneumoniae and
allowed 8 weeks to clear colonization. They were then re-colonized with an
isogenic strain containing a single point mutation that confers resistance to
streptomycin and has no colonization defect (63, 253).

Quantitative RT-PCR
Following lavage with PBS, sacrificed mice were lavaged with 600 µL RLT
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RNA Lysis buffer (QIAGEN) containing 10% 2-mercaptoethanol. Samples
were stored at -80°C until RNA was isolated using a QIAshredder Kit
(QIAGEN) followed by an RNeasy Mini Kit (QIAGEN) per the manufacturers
protocol. Complementary DNA (cDNA) was reverse transcribed using a highcapacity cDNA kit (Applied Biosystems). 10 ng cDNA was used as a template
in each reaction with 0.5 µM forward and reverse primers and Power SYBR
Green (Applied Biosystems) per the manufacturers protocol. Reactions were
amplified with the StepOnePlus Real-Time PCR system (Applied Biosystems)
and comparisons were calculated using the ΔΔCT method. The following
primers were used for amplification: GAPDH-F: 5’-AGG TCG GTG TGA ACG
GAT TTG-3’; GAPDH-R: 5’-TGT AGA CCA TGT AGT TGA GGT CA-3’; IL-1A-F:
5’-GCA CCT TAC ACC TAC CAG AGT-3’; IL-1A-R: 5’-TGC AGG TCA TTT AAC
CAA GTG G-3’; IL-1B-F: 5’-GCA ACT GTT CCT GAA CTC AAC T-3’; IL-1B-R:
5’-ATC TTT TGG GGT CCG TCA ACT-3’; CCL2-F: 5’-AGC TCT CTC TTC CTC
CAC CAC-3’; CCL2-R: 5’-CGT TAA CTG CAT CTG GCT GA-3’; CCL6-F: 5’-ATG
AGA AAC TCC AAG ACT GCC-3’; CCL6-R: 5’-TTA TTG GAG GGT TAT AGC GAC
G-3’; CCL7-F: 5’-GCT GCT TTC AGC ATC CAA GTG-3’; CCL7-R: 5’-CCA GGG
ACA CCG ACT ACT G-3’; CCL8-F: 5’-TCT ACG CAG TGC TTC TTT GCC-3’;
CCL8-R: 5’-AAG GGG GAT CTT CAG CTT TAG TA-3’; IL-17A-F: 5’-TTT AAC
TCC CTT GGC GCA AAA-3’; IL-17A-R: 5’-CTT TCC CTC CGC ATT GAC AC-3’
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Flow Cytometry
PBS lavages from 5 mice were pooled per group, pelleted at 1500 rpm for 10
min and resuspendend in PBS containing 1% bovine serum albumin (BSA).
Samples were first blocked for 10 min in 1% BSA (Sigma-Aldrich) and then
blocked again with a rat anti-mouse FcγIII/II receptor antibody (BD). Cells
were stained for 30 min at 4°C with a cocktail of the following rat anti-mouse
antibodies:

CD4-FITC

(BD),

Ly6G-PE

(BioLegend),

Cd11b-PerCP

cy5.5

(BioLegend), and F4/80-APC (eBioscience).

Quantification of Anti-pneumococcal Serum IgG
The wild type 23F strain used for colonization was grown to mid-log phase in
TS, pelleted, and resuspended in coating buffer (0.015 M Na2CO3, 0.035 M
NaHCO3, pH 9.6) to OD620=0.1. Immulon 2HB 96-well plates (Thermo) were
coated with pneumococci by incubating 100 µL per well of resuspension
overnight at 4°C. Plates were blocked for 1 hr at 37°C in 1% BSA in PBS and
washed with PBS containing 0.05% Brij-35 (Fisher). Serum samples were
serially diluted 2-fold and incubated overnight at 4°C.

The plates were

washed with 0.05% Brij-35 in PBS and pneumococcal-specific antibodies
were

detected

by

incubation

with

a

goat

anti-mouse

IgG

alkaline

phosphatase conjugated antibody for 1.5 hrs at room temperature. Plates
were developed for 1 hr at 37°C using phosphatase subtrate (Sigma) and
read at 415 nm. Geometric mean titers were calculated based on the sample
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dilution where absorbance = 0.1.
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CHAPTER V

Summary and Discussion
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Cytosolic access is dependent on phagocytosis and lysozyme
Our studies define several host factors that are required for S.
pneumoniae

killing

and

subsequent

cytosolic

access

of

pneumococcal

components. Previous work from our lab indicates that this phenomenon
occurs in vivo (60) however, our studies investigated cytosolic access in an in
vitro cell culture system. This was necessary because macrophages in the
upper

respiratory

tract

are

of

low

abundance

and

remain

poorly

characterized. Working in a cell culture system however, allowed us to use
high enough cell numbers that we could quantify cytosolic contents, as well
as employ pharmacologic agents and genetic knock-outs to better dissect the
mechanism of cytosolic access of pneumococcal components. Phagocytosis is
the first step in this host-pathogen interaction and inhibition of bacterial
uptake prevents pneumococcal components from accessing the cytosol. The
scavenger receptor MARCO promotes both bacterial uptake and Nod2dependent sensing of pneumococci in vitro and MARCO-deficient mice have
impaired clearance of S. pneumoniae colonization (67). This indicates that
phagocytosis of pneumococci by macrophages in non-immune hosts occurs
through bacterial binding of this scavenger receptor, which leads to cytosolic
access that triggers Nod2-dependent innate immune signaling cascades.
Once inside the phagosome, pneumococci are subject to a battery of
host defenses, including acidification, proteases, and reactive oxygen species
from the respiratory burst. Previous studies have determined that nitric oxide
contributes to pneumococcal killing by macrophages (167) and our findings
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further

characterize

how

the

host

cell

achieves

destruction

of

the

pneumococcus. Our data show that host expression of the muramidase
lysozyme is required for killing of S. pneumoniae (Fig. 2.2E) and that while
cell wall modifications, which confer bacterial resistance to lysozyme on the
mucosal surface (59), can delay pneumococcal killing by macrophages (Fig.
2.2D), interaction with these professional phagocytes is still fatal for the
pneumococcus. We further observe that access to the cytosol is independent
of phagosome acidification (Fig. 2.5D). This finding is consistent with
lysozyme-mediated

degradation

and

killing,

as

this

muramidase

is

enzymatically active at neutral pH (60).
TLR4 has been reported to directly sense the pneumococcal poreforming toxin pneumolysin in vitro, although the requirement for TLR4
signaling in protection from pneumococcal colonization and invasive disease
remains a subject of debate (19, 65, 162). Our observation that TLR4 is not
required for cytosolic access (Fig. 2.5B) is consistent with other studies
investigating

intracellular

pneumococcal

signaling

infection.

pathways

Pneumolysin

that

triggers

are

activated

by

NLRP3-dependent

inflammasome activation independently of TLR4 (175), and cytosolic access
of

pneumococcal

DNA

activates

type

I

interferon

signaling

without

contribution from TLR4 (208). Given that TLR4 signaling may defend against
S. pneumoniae colonization (162), it remains possible that TLR4 is required
for host defense against pneumolysin activity in epithelial cells rather than in
professional phagocytes.
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Cytosolic access requires pneumolysin
In these studies, we define a critical role for the pneumococcal poreforming toxin pneumolysin in mediating transit of bacterial components to
the

cytosol

of

macrophages.

We

show

that

a

pneumolysin-deficient

pneumococcal strain has significantly impaired cytosolic access (Fig. 2.4B)
and furthermore, the ability of pneumococcal components to access the
cytosol requires pneumolysin binding of cholesterol in host membranes (Fig.
2.4B). We were unable to ascertain whether pore-formation is specifically
required for cytosolic access because a pneumococcal strain expressing a
pneumolysin pore-forming mutant had an intermediate phenotype in our
fractionation assay (data not shown). Pore-formation by pneumolysin is
usually characterized by a hemolysis assay that measures the ability of the
toxin to lyse horse red blood cells. While the pore-formation mutant is almost
completely attenuated in this assay (144, 223, 239), we are unable to say
whether there is still residual toxin activity in the context of pneumococcal
degradation by professional phagocytes.
Our finding that cytosolic access requires both expression of the
pneumolysin toxin and its ability to bind host membranes provides further
insight into how a host discriminates between commensal and potentially
pathogenic microbes. Pneumolysin can facilitate transit of peptidoglycan to
the cytosol of epithelial cells during co-infection with other bacterial species
(222) and other members of the CDC toxin family are well known to
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translocate effector proteins (160) or provide cytosolic access to live
microbes (17, 216) as part of an organisms’ survival. In contrast, the action
of pneumolysin on the host cell coincides with bacterial lysis and does not
directly benefit the bacterium that releases the toxin. Recent work has
characterized intracellular innate immune detection of other extracellular
pathogens that is dependent on expression of their CDC toxins (97),
suggesting that toxin-mediated escape of degraded bacterial fragments from
the phagosome likely occurs for other microbes.
Additional mechanisms of cytosolic access of bacterial components
have been described. A pneumococcal strain expressing a pneumolysin poreforming mutant causes lysosome destabilization at late time points (24 hours
post-infection) (25), though exactly how this occurs is unresolved. Studies
investigating the transit of MDP, the minimal Nod2 ligand (88), to the host
cell cytosol have shown a critical role for the peptide transporters SLC15A3
and SLC15A4 (196). Unlike previous reports linking the peptide transporters
PEPT1 and PEPT2 to the transit of MDP to the cytosol (254, 269), this study
further demonstrates the presence of these transporters and Nod2 on the
phagosome

membrane

during

bacterial

infection

(196).

The

possible

contributions of SLC15A3 and SLC15A4 to cytosolic access of pathogens that
express pore-forming toxins or do not survive in the phagosome provides an
opportunity for future investigation, which could reveal that more than one
route to the cytosol exists for the bacterial ligands that activate innate
immune sensors.
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Cytosolic access results in pro-inflammatory cell death and drives
clearance of colonization
Our observation that inhibition of p38 MAPK increases cytosolic access
of pneumococcal components (Fig. 2.6B) shows that the host cell is able to
sense

and

defend

against

the

action

of

pneumolysin.

P38

MAPK

phosphorylation occurs rapidly in macrophages following incubation with
pneumococci (58), suggesting that this sensing occurs at the plasma
membrane, while the sequelae of p38 MAPK activation limits transit of
bacterial products across the phagosome membrane. Although the host cell
mounts this defense, accessing the cytosolic compartment results in death of
the host cell. Our data demonstrate that this cytotoxicity is dependent on
both bacterial uptake and expression of pneumolysin (Fig. 2.7). This
‘mutually assured destruction’ – death of both the pneumococcus and the
macrophage – may be a strategy by the bacterium to counteract the host
cells responsible for its clearance.
In these studies, we also show that host cell death results in IL-1β
release in vitro and similar to cell death, is dependent on phagocytosis and
bacterial

expression

of

pneumolysin

(Fig.

3.1B).

This

observation

complements results in the literature reporting inflammasome activation and
IL-1β release with a different pneumococcal strain in a variety of cell types
(72, 133, 175). While we were unable to measure levels of mature cytokine
in vivo, Il1r1-/- mice have delayed clearance of colonization (Fig. 3.3A), which
correlates with lower numbers of macrophages in the nasopharynx (Fig.
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3.3E), suggesting that sensing of IL-1 cytokines that results from cytosolic
access contribute to bacterial clearance. However, our results demonstrate
that expression of Il1a and Il1b increases upon colonization in a manner that
is dependent on TLR signaling (Fig. 3.2), a finding that is consistent with
cellular priming for inflammasome activation.
Previous work from our lab defined a critical role for the intracellular
host

receptor

Nod2

in

clearance

of

pneumococcal

colonization

(60).

Interestingly, these studies found that clearance of colonization was most
significantly impaired in mice deficient in both Nod2 and TLR2, suggesting
redundancy between these two pattern recognition receptors. Our studies
define an additional intracellular innate immune pathway that is dependent
on TLR stimulation, which is activated by S. pneumoniae and contributes to
bacterial clearance from the host. It is therefore possible that both Nod2
sensing and IL-1 cytokines contribute to clearance of pneumococci from the
nasopharynx and that cytosolic access is the unifying event that triggers both
of these host sensing mechanisms.
Activating multiple innate immune pathways may also have significant
contributions to host protection from pneumococcal disease. Children with
deficiencies in either MYD88 or IRAK-4, molecules that are downstream of
TLRs and the IL-1 receptor, experience recurrent pneumococcal disease (21,
146, 213) that cannot be attributed to loss of TLR function alone (182). This
implies that sensing of IL-1 cytokines, in addition to TLR activation, may
have a critical role in defense against S. pneumoniae.
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Why the pneumococcus would make a toxin that activates innate
immune signaling that drives the host to clear it from its niche is a logical
question resulting from these studies. Our observation that IL-1 sensing
promotes inflammation in the nasopharynx without further contributing to
the development of adaptive immune responses may provide some answers.
The host inflammatory response to pneumococcal colonization promotes both
bacterial growth (247) and transmission (244); therefore, production of IL-1
cytokines during colonization may contribute to inflammation that promotes
the pneumococcus’ lifestyle without impacting its ability to re-colonize the
same host at a later time.

Model of cytosolic access of pneumococcal components
Based

on

our

studies

interrogating

the

mechanism

by

which

pneumococcal components access the host cell cytosol, we propose a model
of cytosolic access with critical roles for bacterial degradation by lysozyme
and the function of the pore-forming toxin pneumolysin (Fig. 4.1). The
presence of bacterial products in the cytosol is dependent on phagocytosis,
indicating that bacterial uptake initiates this host-pathogen interaction.
Killing

of

S.

pneumoniae

occurs

rapidly

following

phagocytosis

and

pneumococcal degradation is delayed by bacterial modifications that confer
resistance to lysozyme or in macrophages that are lysozyme-deficient. These
findings demonstrate that lysozyme significantly contributes to bacterial
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killing by macrophages. A lysozyme sensitive pneumococcal strain has
increased amounts of bacterial components in the host cell cytosol, indicating
that lysozyme degradation is also important for generating bacterial
fragments that transit to the cytosol. Lysis of the bacterial cell causes the
release of the pore-forming toxin pneumolysin, which is required for
pneumococcal components to access the cytosol. Additionally, the ability of
the toxin to bind cholesterol in the host membrane is necessary for cytosolic
access to occur, demonstrating a critical role for toxin function in this
phenomenon. The host is able to detect and limit toxin activity through p38
MAPK activation, though ultimately these defenses are insufficient and the
macrophage

undergoes

a

pro-inflammatory

cell

death.

Death

of

the

macrophage results in the release of IL-1β and sensing of IL-1 family
cytokines is required for successful macrophage recruitment and clearance of
colonization (Fig. 4.2). The mechanism by which IL-1 cytokines promote
macrophage-driven bacterial clearance is unknown, but provides an avenue
of future inquiry.

Future Directions
The role of p38 MAPK activation in vivo
Our finding that p38 MAPK sensing of pneumolysin limits cytosolic
access further contributes to the body of evidence that this signaling pathway
is critical for defense against pore-forming toxins (116, 118, 223). Exactly
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how p38 MAPK activation achieves this defense of the host cell is unclear and
could be the subject of future investigation. Furthermore, the significance of
p38 MAPK activation during pneumococcal colonization in vivo remains to be
addressed. Studies of pneumococcal pneumonia have shown that p38 MAPK
activation is critical for controlling bacterial burden (266), suggesting an
important role for this signaling cascade in bacterial clearance at the mucosal
surface and also demonstrating that inhibition of p38 MAPK can be achieved
in vivo. However, the contribution of pneumolysin to p38 MAPK activation
was not addressed in this study. In addition to pore-forming toxins, TLRs can
activate P38 MAPK signaling and the contribution of pneumolysin or other
pathogen associated molecular patterns in p38 MAPK-mediated defense
during pneumococcal disease or colonization is still an open question.

Determine the contributions of IL-1α and IL-1β to clearance of colonization
Our findings define a critical role for sensing by the IL-1 receptor in
detection and clearance of pneumococcal colonization, although we have not
demonstrated

which

IL-1

receptor

agonists

are

responsible

for

this

phenotype. The type 1 IL-1 receptor is activated by binding of both IL-1α and
IL-1β (84). While we show that IL-1β expression is highly induced during
colonization (Fig. 3.2B) and administration of recombinant IL-1β is sufficient
to promote a reduction in bacterial carriage (Fig. 3.3F), we have not
excluded a potential contribution of IL-1α in the host immune response to
pneumococcal

!

colonization.

Attempts
109!

to

neutralize

IL-1α

and

IL-β

in

colonized mice by intraperitoneal injection of monoclonal antibodies at
concentrations that are effective on the mucosal surface (42) did not
significantly alter clearance of colonization at 14 days post-infection (data not
shown). Nasal lavages are highly diluted and we could not detect cytokines in
samples from the upper respiratory tract; therefore, we were unable to
confirm cytokine depletion upon treatment with the neutralizing antibodies.
To specifically address which IL-1 receptor ligands contribute to
bacterial clearance from the nasopharynx, we could examine the dynamics of
colonization in IL-1α or IL-1β-deficient mice (112, 113, 128). Following
inoculation of these mice with S. pneumoniae, we would be able to assess
bacterial burden and immune cell infiltrate over time and determine whether
the absence of IL-1α or IL-1β alone phenocopies our findings from Il1r1-/mice. We could also generate mice that lack both IL-1α and IL-1β to
determine if these cytokines have redundant or synergistic contributions to
clearance of colonization. These experiments would clarify the individual
contributions of both IL-1α and IL-1β to the host immune response to S.
pneumoniae colonization.

Characterize the role of CCL6 in S. pneumoniae colonization
Our observation that Il1r1-/- mice have lower expression of the
macrophage chemokine CLL6 than WT mice during colonization gives rise to
several avenues of further inquiry. Neutralization of CCL6 with depleting
antibodies in colonized WT mice could show whether CCL6 is necessary for
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clearance of pneumococci. This experiment, however, may have similar
technical challenges in verifying depletion as the IL-1α and IL-1β depletion
experiments we have previously performed. Although CCL6 is a known
macrophage attractant (147), it will be important to demonstrate if CCL6 is
sufficient to recruit macrophages in the environment of the upper respiratory
tract. To address this, we could intranasally administer exogenous CCL6 to
colonized Il1r1-/- mice and monitor the presence of immune cell infiltrates,
specifically the population of monocytes/macrophages, in lavages of the
nasopharynx. We could also monitor whether administration of recombinant
cytokine has an effect on bacterial clearance.
Determining which cells in the respiratory tract are the source of CCL6
is another question that remains to be addressed. CCL6 is produced by
cultured macrophages (147, 207), as well as epithelial cells of the gut (145),
making both of these cell types potential candidates. Furthermore, mRNA
present in RLT lysis lavages of the upper respiratory tract is predominantly
derived from epithelial cells of the mucosal barrier, suggesting that they are
likely to be a source of CCL6. To test this hypothesis, we could section the
upper respiratory tracts of mock infected or colonized mice and conduct
immunofluorescence staining and imagining for the presence of CCL6. As
CCL6 is a secreted protein, it may still be difficult to detect this chemokine
within any cell population in vivo, in which case, in vitro cell culture could be
informative.
To address the potential contribution of macrophages to the production
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of CCL6, we could infect bone marrow-derived macrophages with S.
pneumoniae and monitor for the transcription and production of C-C motif
chemokines, including CCL6. Similar experiments have characterized CCL2
production by macrophages (60), and macrophages elicited in a model of
irritant peritonitis are sources of CCL6 at later time points (147, 285).
CCL6 has been identified only in rodents and has two human
homologs, CCL14 and CCL15, which share 36 and 53 percent amino acid
identity with CCL6, respectively (145). The lack of a clear homolog in
humans is a limitation of using a murine model. Therefore, determining
whether either, or both, CCL14 and CCL15 are expressed as a result of S.
pneumoniae sensing will be important for relating our findings to human
carriage or disease. If prior experiments in murine cells show that
macrophages produce and secrete CCL6 upon pneumococcal infection, we
could perform similar experiments with human macrophages differentiated
from blood monocytes and assay for both CCL14 and CCL15. Alternatively,
we could use the monocyte derived THP1 cell line, that can phagocytose and
kill pneumococci (225). Studies investigating chemokine production during S.
pneumoniae infection have characterized a role for macrophage-produced IL1β in driving production of the neutrophil chemokine CXCL8 by epithelial cells
(168). We could conduct co-culture experiments in vitro to address the
possibility

that

macrophage

infection

with

S.

pneumoniae

results

in

production of IL-1 cytokines that are sensed by the epithelium, which then
drives

!

CCL14

or

CCL15

expression
112!

and

secretion.

Together,

these

experiments will better define the relationship between S. pneumoniae
colonization, IL-1 family cytokines, and chemokine production.

Determine the contribution of cytosolic access in colonization of other
mucosal pathogens
Ascertaining whether our findings can be generalized to other
extracellular pathogens is a broader area of possible future inquiry. The
implications for carriage of Staphylococcus aureus are of specific interest,
particularly because S. aureus is second only to S. pneumoniae as a cause of
pyogenic infections in MYD88 and IRAK-4-deficient patients (146). Similar to
the pneumococcus, S. aureus is a colonizer of the host mucosal surfaces and
can exist as both a pathogen and a commensal. While S. aureus can be
isolated from non-mucosal surfaces such as the skin and frequently causes
wound and soft tissue infections, the anterior nasopharynx is the most
common site of colonization in humans (279). Carriage in the nasopharynx is
believed to be the reservoir for colonization of other body sites and the
source of disease (69).
There is evidence that cytosolic access of S. aureus bacterial
components occurs during infection and is important for host defense. Nod2
sensing is dependent on S. aureus expression of the pore-forming α-toxin
and is critical for host control of cutaneous infection (115). Furthermore, S.
aureus activates the NLRP3 inflammasome in macrophages in a manner that
is dependent on lysozyme (243), though this pro-inflammatory cell death
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may contribute to immunopathogenesis during pulmonary infection (135).
The role of this innate immune recognition to S. aureus colonization and
carriage is unknown.
Colonization by S. aureus has historically been challenging to study
due to the paucity of identified strains that can establish and persist in
mouse models (154). Recently, studies have identified strains that colonize
the murine anterior nasopharynx for a duration of weeks (5, 111), allowing
an opportunity to better examine the role of host innate immune responses
to S. aureus carriage.

Concluding Remarks
Accessing

the

cytosol

is

considered

a

conserved

motif

among

pathogenic organisms (268) and host detection of cytosolic access is
essential

for

discrimination

between

a

pathogen

and

a

commensal.

Intriguingly, Streptococcus pneumoniae, a leading extracellular pathogen,
activates intracellular innate immune signaling pathways, which contributes
to host defense against colonization and disease by this organism. The
studies presented here focused on the mechanism and consequences of
cytosolic access by S. pneumoniae.
While many microbes access the cytosol to promote their replication,
cytosolic access of pneumococcal components follows a fatal event for the
pneumococcus. Our studies show that bacterial products access the cytosol in
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a manner that is dependent on the pore-forming toxin pneumolysin and
suggest that lysozyme degradation in the phagosome triggers toxin release.
Detection of the virulence activity of a pore-forming toxin, even if it is
produced by a microbe a phagocyte has killed, may provide the host a signal
that this organism is potentially pathogenic and should be cleared although it
is not causing disease.
We further demonstrate that cytosolic access results in phagocyte
death and release of cytokines that promote inflammation, immune cell
recruitment,

and

development

of

bacterial
adaptive

clearance,
immunity.

but

do

not

contribute

to

the

Inflammatory

responses

in

the

nasopharynx may promote pneumococcal growth and transmission and our
findings

provide

important

new

insights

into

the

dynamics

of

the

pneumococcus’ lifestyle and the potential contribution of its pore-forming
toxin pneumolysin.
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Figure 4.1. Model of cytosolic access of pneumococcal components.
(A) S. pneumoniae is phagocytosed and subsequently degraded by lysozyme.
This releases the pore-forming toxin pneumolysin (Ply), which facilitates
transit of bacterial components across the phagosome membrane to the
cytosol. There, they activate Nod2 signaling, resulting in cytokine production
and eventually clearance of colonization. Host sensing of Ply activates p38
MAPK signaling, which limits cytosolic access however, this phenomenon is
fatal for the macrophage (MΦ) and results in host cell death.
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Figure 4.2. Model of IL-1 sensing and clearance of pneumococcal
colonization.
(A) Cytosolic access of pneumococcal components occurs after degradation
by lysozyme and release of pneumolysin (Ply). This event triggers
inflammasome (NLRP3 and AIM2) formation that leads to activation of
caspase-1 and secretion of interleukin-1 beta (IL-β) and possibly interleukin1 alpha (IL-1α). Sensing of IL-1 cytokines by the IL-1 receptor (IL-1R)
promotes clearance of S. pneumoniae colonization, potentially through
increased levels of the macrophage attractant C-C motif chemokine 6
(CCL6).
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